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2017 Statistics 
at a Glance 
EXPORT CERTIFICATES ISSUED – 
1,486 CERTIFICATES FOR MEDICINES 
AND 2,371 FREE SALE CERTIFICATES 
FOR MEDICAL DEVICES
3,857
OUR ASSESSMENT RATING 
OUT OF 5 UNDER BEMA, THE 
BENCHMARKING PROGRAMME FOR 
EUROPEAN MEDICINES AGENCIES
4.5
THE TOTAL NUMBER OF NEW 
HUMAN MEDICINES AUTHORISED
684
THE NUMBER OF PATIENTS WHO 
COMPLETED THE HPRA MODULE OF THE 
IPPOSI PATIENT EDUCATION PROGRAMME
20
APPLICATIONS FOR NEW CLINICAL 
INVESTIGATIONS OF MEDICAL 
DEVICES 
9
NEW MARKETING AUTHORISATIONS 
ISSUED FOR VETERINARY MEDICINES
152
MANUFACTURING LICENCES IN 
PLACE AT YEAR END – 111 FOR 
HUMAN MEDICINES AND 20 FOR 
VETERINARY MEDICINES
131 
CLINICAL TRIALS OF HUMAN 
MEDICINES WERE APPROVED TO 
COMMENCE IN IRELAND
96
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EU PSUR SINGLE ASSESSMENT 
PROCEDURES FOR HUMAN MEDICINES 
LED BY THE HPRA
29 
REGULATORY INFORMATION 
SEMINARS HOSTED – IN LEITRIM, 
LIMERICK AND DUBLIN – FOR OUR 
COSMETIC STAKEHOLDERS
3
SUSPECTED ADVERSE REACTION 
REPORTS FOR HUMAN MEDICINES 
RECEIVED
4,402
MARKET SURVEILLANCE CASES 
UNDERTAKEN IN RESPECT OF MEDICAL 
DEVICES
1,281
UNITS OF ILLEGAL PRESCRIPTION MEDICINES DETAINED IN 
IRELAND DURING PANGEA X
200,000 
MEDICINE RECALLS CONSISTING 
OF 82 HUMAN MEDICINES AND 7 
VETERINARY MEDICINES
89
GMP INSPECTIONS CONDUCTED AT 
MANUFACTURING SITES FOR HUMAN 
AND VETERINARY MEDICINES, AND 
ACTIVE SUBSTANCES
118
MEDICAL DEVICE VIGILANCE REPORTS 
RECEIVED AND ASSESSED
2,339 
REPORTS OF SUSPECTED ADVERSE 
REACTIONS ASSOCIATED WITH USE 
OF VETERINARY MEDICINES
397
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It is a great pleasure to introduce the 2017 
annual report, which outlines the extensive 
work of the HPRA over the past 12 months.  
As Chair of the HPRA, I see my role as being to work 
with the members of the Authority to support the 
Chief Executive and the members of the executive 
team in our mission to continually protect and enhance 
public and animal health. As outlined in my report 
last year, we are guided by our strategic plan and we 
depend ultimately on having dedicated, qualified 
and experienced staff to deliver on our ambitions. 
This is how we ensure that the highest standards 
of excellence and capabilities are maintained and 
continually evolve so as to meet all our stakeholders’ 
needs into the future.  
In order to measure our effectiveness as an 
organisation, we engage in external benchmarking 
programmes with our counterparts across Europe. The 
learnings from such reflective and thorough analysis 
continue to drive the HPRA’s ambition to deliver better 
outcomes for patients and members of the public.  
In this respect, I would like to highlight two significant 
developments in 2017; our involvement in the 
Joint Audit Programme (JAP) for inspections and 
our participation in the Benchmarking of European 
Medicines Agencies (BEMA).
The European Heads of Medicines Agencies (HMA) 
Joint Audit Programme is an external benchmarking 
process. The HPRA’s quality system for good 
manufacturing practice (GMP) – incorporating 
inspection and licensing of manufacturers of 
medicines, management of quality defects and 
recalls, and sampling and analysis of medicines – was 
evaluated under this programme in May. The audit 
was observed by the US FDA as part of its review 
of equivalency of our systems in relation to the US/
EU mutual recognition agreement (MRA) on GMP 
inspections. The audit was successful, validating the 
strength of the HPRA’s processes and procedures 
for inspection and quality defect management. As a 
result, I look forward to the significant achievement of 
Ireland’s anticipated inclusion as a country recognised 
under the MRA during 2018. 
This was followed in October by the HPRA’s 
participation in BEMA, the benchmarking programme 
for European human and veterinary medicines 
agencies which is now in its fourth cycle. This 
programme aims to contribute to the development of 
a world-class pharmaceutical regulatory system across 
Europe, based on a network of agencies consistently 
employing recognised best practices. The HPRA’s 
assessment, which was carried out by representatives 
from three other EU regulatory agencies, resulted in an 
excellent overall rating of 4.5 (out of 5). Of particular 
note, there was a top rating of 5 for nine specific 
indicators. 
One of those indicators related to human resources 
and I am very proud of the emphasis that the Authority 
places on the development of its most important 
asset, its staff. In 2017, we saw the second year of 
activity under the organisation’s HR Strategy and 
the commencement of the HPRA’s Management 
Development Programme focusing on developing 
leadership capabilities and talent management. 
This investment in our people managers is central 
to developing the internal capabilities across the 
organisation for now and into the future. Investment in 
technical expertise was also a key priority in 2017.  
As an organisation, the HPRA always strives to develop 
new approaches to foster engagement and ensure we 
best serve public and animal health. For many reasons 
2017 was a notable year in this regard. For example, as 
outlined by our Chief Executive in her 2017 Report, the 
management of Brexit and its potential implications in 
terms of medicines availability, has brought about the 
need for a different approach to our engagement with 
patients and healthcare professionals for the purposes of 
ensuring effective management of this situation. 
The Authority also recognises the importance 
of transparent and open communication with 
our stakeholders, especially patients, healthcare 
professionals and members of the public. During 2017, 
a number of new initiatives were progressed to enhance 
and develop our communications. I look forward to 
working further with the Authority and HPRA staff in 
shaping and evolving the work that has commenced and 
I intend to report more fully on this in next year’s annual 
report.
Forward Focus
Looking ahead, the members of the Authority and 
I are ever conscious that the HPRA faces a range of 
opportunities and challenges in 2018. These include 
management of a changing complex regulatory 
environment in Europe across many areas including 
medical devices, clinical trials and veterinary medicines, 
supporting innovation and, of course, Brexit. All of these 
activities will be addressed and prepared for alongside 
the critical routine work of the organisation and its 
ongoing development of capabilities and support 
services. We are greatly assured by the expertise, 
preparedness and pragmatic approach of the agency 
staff in addressing its many priorities.
Over the coming years, working together, we will ensure 
that the HPRA remains alert and agile with the capability 
and capacity to anticipate and meet the demands of a 
rapidly changing external environment. As always, we 
remain fully committed to our constant and common 
goal of protecting the health and safety of all those who 
use health products.
Acknowledgments 
On behalf of the Authority, I thank the Minister for 
Health, the Minister for Agriculture, Food and the 
Marine, their advisors and the staff of their departments 
for their ongoing support of the HPRA and its activities. 
I would particularly like to thank the Chief Executive, 
management and all the staff and to acknowledge the 
excellence of their work. The very significant progress 
and results achieved in 2017 are clearly reflected 
throughout this report. 
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Authority  
Members
The Authority of the HPRA is appointed by the Minister 
for Health in accordance with the powers conferred by 
subsection 2 of section 7 of the Irish Medicines Board Act, 
1995. There were nine Authority members up to  
31 December 2017.
Prof. Caitriona O’Driscoll Dr. Diarmuid QuinlanProf. Elizabeth Keane
Mr. David Holohan
Ms. Ann Horan 
(Chairperson)
Prof. Mary Horgan
Mr. Pat Brangan
Mr. Brian JonesMr. Wilfred J. Higgins
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Management 
Committee
Dr. Lorraine Nolan  
Chief Executive
 
Mr. Kevin Horan 
Director of ICT and 
Business Services 
Mr. John Lynch  
Director of Compliance
Ms. Lynsey Perdisatt 
Director of Human  
Resources and Change 
Dr. Joan Gilvarry  
Director of Human  
Products Monitoring
Dr. J.G. Beechinor 
Director of  
Veterinary Sciences
Dr. Jayne Crowe  
Director of Human 
Products Authorisation  
and Registration
Dr. Caitríona Fisher 
Director of Quality, 
Scientific Affairs and 
Communications
Ms. Rita Purcell  
Deputy  
Chief Executive
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In preparing my third foreword to the 
Annual Report since I was appointed as 
Chief Executive in January 2016, I have been 
struck by how it has been a very busy year 
that has seen many new opportunities and 
developments emerge. It continues to be my 
privilege to lead a dynamic agency that makes 
a major and tangible contribution every day 
to safeguarding public and animal health in 
Ireland and beyond.
2017 resulted in some clear step changes for the 
Health Products Regulatory Authority (HPRA) and the 
continued progression of our organisation in line with 
the goals set by our 2020 Strategic Plan. During the 
year, we made significant inroads in advancing our 
processes for direct engagement with patients and 
the public, healthcare professionals and innovators. I 
believe that this progress brought about in 2017, which 
is further expanded below, is changing the way in 
which we are connecting with our key stakeholders and 
is delivering more meaningful two way engagement. In 
addition to positioning the HPRA as being accessible 
and approachable in terms of our remit of protection 
of public and animal health, developments in 2017 
have ensured that the value-add of our regulatory 
approach continues to be better understood by our 
stakeholders. It has also played a significant role in 
informing us on how we should continue to grow and 
develop our organisation into the future.  
Stakeholder Engagement and 
Communications
One of the developments from 2017, which I am 
particularly proud of, was the execution of our role as 
an education partner in the Irish Platform for Patient 
Organisations, Science and Industry (IPPOSI) Patient 
Education Programme. The HPRA’s contribution 
focused on the areas of regulatory affairs, medicinal 
product safety and pharmacovigilance. This initial 
programme, tailored for Irish patient communities, 
concluded with the graduation of 20 expert patients 
who will play an important role in sharing their 
knowledge and experiences for the benefit of others. 
The HPRA, through our colleague Almath Spooner, the 
Vice-Chair of the Pharmacovigilance Risk Assessment 
Committee (PRAC), was centrally involved in the first 
ever public hearing at the European Medicines Agency 
(EMA) held in September. This unique opportunity to 
give EU citizens a voice in the evaluation of the safety 
of medicines and empower them to express their 
views on issues related to the management of risks, is 
something to emulate at national level. In 2017, our 
mechanisms for engagement with patient groups and 
healthcare professionals have been further enhanced 
to involve greater use of multi-stakeholder discussion 
forums for key medicines safety issues. This is 
something we believe will better serve the public as it 
will deliver greater alignment between health product 
regulation and healthcare provision. 
As an organisation, the HPRA is completely committed 
to ensuring that the market for health products in Ireland 
is highly and appropriately regulated to enable the 
highest standards of public and animal health protection. 
Consistent with this, we continue to apply our expertise 
to ongoing safety assessment and monitoring of 
authorised medicines on the market whilst utilising our 
regulatory powers as required. Simultaneously, we place 
considerable focus on minimising the entry of illegal 
medicines to the marketplace. In this regard, Operation 
Pangea again highlighted the significant collaboration 
taking place between the health product regulators, 
law enforcement agencies and the private sector in 
combating the illegal supply of medicines and medical 
devices on an annual basis. The 2017 operation, which 
represented the tenth year of Pangea, took place in 
September, and was led by the HPRA in partnership with 
Revenue’s Customs Service and An Garda Síochána. It 
resulted in the detention of over 200,000 units of illegal 
prescription medicines, a threefold annual increase. 
This outcome was a result of enhanced intelligence-
led enforcement activities building successfully on 
our strong year-round collaboration with our partner 
agencies. Globally, Pangea led to over 25 million illegal 
medicines and medical devices worth over US$56 million 
being detained across 123 countries. Significantly, from 
a public health perspective, this enforcement operation 
also provided the HPRA and our partner organisations 
with a key opportunity to highlight the serious risks 
involved in sourcing illegal prescription medicines and 
medical devices online, many of which are from dubious 
sources and may be counterfeit.
Supporting Innovation
In 2017, we also continued to identify ways to support 
and facilitate product development for patients in 
need of new treatments by further improving early 
engagement with key stakeholders. The Innovation 
Office at the HPRA was established in late 2016 with 
our first innovation stakeholder event to provide a 
platform for sharing knowledge and information taking 
place in May 2017. The conference brought together 
researchers, entrepreneurs and other interested parties 
from various sectors including academia, research 
organisations, SMEs and the life sciences industries. 
Enhancing communication and strengthening the 
links between academia, industry and regulators is a 
critical support for a sector which is highly dynamic and 
innovative. This area was a key focus for us during the 
year as we continued to build on our programme of 
outreach with the sector which first commenced in 2016. 
Our focus on innovation also extended to involve 
greater contribution at European level, through the 
Innovation Network, and internationally. Specifically, we 
assumed a role in supporting innovation through our 
participation in the International Coalition of Medicines 
Regulatory Authorities (ICMRA) which established a 
new strategic priority in innovation during the year. This 
priority includes a work stream, focusing on outcomes of 
horizon scanning, which is jointly led by the HPRA and 
the EMA. 
Brexit
Many of the advancements we made in 2017 were 
brought about as part of our proactive approach to 
managing the significant challenges presented by the 
United Kingdom’s decision in 2016 to withdraw from the 
EU. Our focus since this announcement has always been, 
and will continue to be, public health protection. The 
HPRA hosted a Brexit stakeholder event in August 2017, 
the first such event hosted by a competent authority in 
Europe. Brexit has potentially significant implications 
for the European regulatory network as a whole and 
particularly for Ireland given our shared marketplace with 
the UK. We have confirmed our commitment to support 
the European network to ensure that the resources and 
capacity required are available to guarantee an orderly 
redistribution of the work currently undertaken by the 
UK and we will continue to position our agency to swiftly 
contribute to addressing any additional issues that may 
arise from the UK’s exit. Through this preparedness, and 
our support of the EMA’s relocation to Amsterdam, we 
will assist the smooth continuation of EMA activities and 
help to deliver the network’s shared goal of protecting 
human and animal health in Europe at all times. 
Nationally, the HPRA is fully committed to working to 
ensure that the availability of medicines and other health 
products is not negatively impacted by Brexit and we 
have been proactively focused on supporting measures 
to ensure sustainable levels of product marketing 
authorisations in Ireland. 
One of the consequences of Brexit is that the EMA has 
to relocate from its present location in London. During 
2017, the HPRA, working with colleagues from the 
Department of Health and IDA Ireland, as well as other 
Government officials and diplomats in Brussels and 
throughout Europe, led the development of a proposal 
to have the Agency relocated to Dublin. Ireland was one 
of nineteen countries that submitted proposals to the 
European Commission. The decision was subsequently 
made through the European Council in September and 
Amsterdam was chosen as the new location for the 
Agency. The HPRA looks forward to supporting both the 
HPRA Annual Report 2017
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EMA and the European network in ensuring a successful 
transition to the new location in the Netherlands which 
will begin during 2018. 
Although Dublin was not the chosen location, the 
preparation of the proposal, the strength of which was 
recognised by numerous stakeholders, was a unique 
opportunity to showcase the many strengths of Ireland 
in relation to the wider life sciences sector, our access to 
scientific talent and the strong regulatory environment 
that has been established by the HPRA. It was a great 
pleasure to work with our Government colleagues 
on this project, which was of significant strategic 
importance from the perspective of public health and 
promoting Ireland’s economic interests and reputation 
internationally.
Separate to Brexit, but nonetheless related, the HPRA 
established a new project on medicines shortages in 
2017. This followed a request by the Department of 
Health for the HPRA to undertake a role in the national 
coordination of medicines shortages following a review 
it convened under its Medication Safety Forum. Due to 
a range of factors, medicine shortages are increasing 
in prevalence and affecting all the global regions. The 
HPRA-led project is focused on developing enhanced 
methods and devising new solutions to ensure better 
coordination among key stakeholders in Ireland for 
both the prevention and management of medicines 
shortages. The objective is to develop a national 
protocol for management of shortages to ensure better 
patient outcomes and enhanced communication and 
engagement on this key public health issue.
Building Internal Capabilities
The environment in which we operate is fast paced, 
dynamic and evolving. Our strategic goals drive us to 
develop our internal capabilities and plan for future 
expertise requirements in line with the constant 
development of new and innovative health products 
and technologies. In the past year, our focus has been 
on attracting new talent with diverse and expert skills in 
the areas of software, analytics and new areas of clinical 
interest. In addition, we have continued to invest in the 
development of the skills and expertise of our staff. 2017 
saw further developments under our HR strategy, which 
sets out a five-year roadmap for talent development 
within the HPRA. Key deliverables achieved last year 
include the launch of our Management Development 
Programme.
All the while, our regulatory environment continues 
to evolve. Indeed, during 2017, political agreement 
was reached on the new medical devices regulatory 
framework for Europe. This is a significant development 
in further strengthening the regulatory environment 
within which we operate to provide further protection 
for patients and users of medical devices. It also requires 
the HPRA to continue to evolve and develop our 
approach so that as an organisation we can continue 
to deliver a robust system of regulation for medical 
devices which meets current and future needs. A key 
focus for the year ahead will be reshaping our internal 
structures and processes for medical devices to allow 
us to effectively deliver our remit in the context of the 
revised framework and, most importantly, to best serve 
the needs of Irish patients.
10 HPRA Annual Report 2017
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Network Participation
Throughout the year, the agency has worked very closely 
with our European counterparts through representation 
on a wide range of committees and working groups 
at the EMA and within the Heads of Medicines 
Agencies’ network, as well as at a bilateral level. HPRA 
representatives continued to hold the substantial roles 
of Chair of the EMA’s Committee for Medicinal Products 
for Veterinary Use (CVMP) and Vice-Chair of the EMA’s 
Pharmacovigilance Risk Assessment Committee (PRAC). 
We have also continued to grow our participation and 
footprint within international networks through our work 
in the International Coalition of Medicines Regulatory 
Authorities and the International Medical Device 
Regulators Forum. The work of both these groups aims 
to enhance global harmonisation among regulators. As 
an agency, we are honoured to be the host and are very 
much looking forward to the World Health Organisation’s 
International Conference of Drug Regulatory Authorities 
(ICDRA) in Dublin in 2018 and work continued during 
the past year in preparation for this major event.
A Look Forward
The HPRA regulates a wide range of health products in 
Ireland. Indeed, as a regulator of ten classes of health 
products across nine regulatory regimes, we have one 
of the widest remits when compared to other agencies 
internationally. We set ourselves high standards and are 
well placed to continue on our planned development 
trajectory. To achieve our potential, we must reflect 
on our achievements in 2017 and plan for the known 
and indeed the unknown opportunities and challenges 
that lie ahead. Our investment in building internal 
capabilities, stakeholder engagement and innovation 
supports, position us well as we continue on our journey 
to meet the challenges of being a regulator of the 
future.
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The HPRA grants licences for medicines 
subject to a review of their safety, quality and 
effectiveness and continuously monitor their 
use once they become available on the Irish 
market. We also approve and monitor clinical 
trials, inspect and license manufacturing sites 
and wholesalers, and investigate activities 
associated with the illegal supply, manufacture 
or advertising of medicines.
Authorisation and Registration
• Prior to a new medicine being placed on the Irish 
market, it must be assessed and authorised (licensed) 
by the HPRA or by the European Medicines Agency 
(EMA) in conjunction with the European Commission. 
The assessment involves establishing that a 
medicine’s health benefits outweigh its known risks. 
Where this is the case, it may be granted a marketing 
authorisation.
 There are a number of routes through which a 
product can be authorised by the HPRA. These 
include the national procedure, the mutual 
recognition procedure (MRP) and the decentralised 
procedure (DCP). Both MRP and DCP involve the 
simultaneous submission of applications in a number 
of EU Member States. 
 The centralised route is coordinated by the EMA and 
results in an authorisation which is granted by the 
European Commission and is valid across Europe. 
The assessment is carried out by Member States 
appointed as lead assessor (rapporteur), joint lead 
assessor (co-rapporteur) and peer reviewer, with 
input also from all other Member States.
 During the year in review, the total number of 
new medicines authorised in Ireland was 684. 
This compares to 637 in 2016. The 2017 figures 
incorporate: 
– 104 new national applications which includes 99 
parallel import applications; 
– 58 applications made under the MRP and 324 
applications made under the DCP. The HPRA 
acted as reference (lead) Member State for the 
assessment of 12 of the DCPs.
– 2 rapporteurships and 10 co-rapporteurships 
under the centralised route. A number of these 
applications were for biological medicines. 
– An additional 186 medicines authorised through 
the centralised route where the HPRA was neither 
rapporteur nor co-rapporteur.
• In 2016, we established a new national scientific 
advice procedure to assist commercial and non-
commercial entities in the development of new or 
existing medicines or making applications for clinical 
trial authorisation or marketing authorisations. This 
service complements advice which we provide on 
earlier stage product development through the 
Innovation Office as well as scientific advice provided 
at an EU level through the EMA’s Scientific Advice 
Working group. During the year:
– We continued a pilot study based on a number of 
national scientific advice meetings. Six meetings 
were held as a result of which we were able to 
review the cumulative experience gained over the 
nine months of the pilot. 
– Our external guidance document for stakeholders 
was revised and published to our website. 
– Initial discussions were held with the National Centre 
for Pharmacoeconomics in late 2017 in respect 
of horizon scanning, early scientific advice, the 
EMA-EUnetHTA three-year work plan and patient 
education. 
• Timely access to medicines is critical for patients so 
they can benefit from new and promising therapies 
and a number of procedures are available to assist in 
this. During 2017:
– The HPRA secured its first rapporteurship for a 
medicine under the EMA’s PRIME scheme which 
offers early support to developers so they are better 
positioned to generate robust data on the medicine 
and enable accelerated assessment of the marketing 
authorisation application.
– A total of 96 new clinical trials were approved 
to commence in Ireland; 19 of these related to 
voluntary harmonisation procedures for clinical trials 
with the HPRA acting as lead Member State for five 
of these co-ordinated work-sharing assessments for 
multinational clinical trials. 
• Reclassification of the legal status of medicines aims to 
increase the number of medicines available to patients 
without prescription where it is safe to do so. This 
year: 
– One prescription-only medicine for pain relief was 
authorised for non-prescription, pharmacy-only sale 
while another pharmacy-only medicine, indicated 
for nicotine replacement therapy, was reclassified to 
general sale. 
• In June 2013, the HPRA commenced publication of a 
list of interchangeable medicines to facilitate generic 
substitution by pharmacists and to allow for reference 
pricing by the Health Service Executive (HSE). By year 
end, the interchangeable medicines list included 60 
active substances.
• A biosimilar medicine is a biological medicine that is 
very similar to an original biological medicine called 
the reference medicine. 
– During 2017, we published an online questions and 
answers document which was developed in plain 
English and approved by the National Adult Literacy 
Agency (NALA) prior to completion in November. 
In addition, we commenced work on a plain English 
video.
– Also in November, the HPRA hosted a successful 
information evening for healthcare professionals to 
outline how biosimilar medicines are approved for 
use in patients. 
– During the year, we delivered a series of 
presentations at external events to inform healthcare 
professionals and patients about the use of 
biosimilars. Staff members also contributed to a 
number of peer-reviewed papers and conference 
papers that focused on this topic. 
– The HPRA’s biosimilars project in conjunction 
with Regulatory Science Ireland was successfully 
completed in 2017 with all elements of the work 
plan accomplished. The research scientist who 
commenced work on this project in January 2016 
submitted her thesis entitled ‘The Regulatory 
Science of Biosimilars’ to University College Cork in 
December 2017. 
• Medicine shortages have been an ongoing concern 
globally and in Ireland for some years. Under 
our current strategic plan, we have committed 
to establishing a system for co-ordinating the 
management of shortages. During 2017:
– We commenced a project, following Department of 
Health approval, to design and implement a system 
for co-ordinating the management of shortages. In 
Q4, we conducted an intense phase of stakeholder 
engagement, meeting with patient groups, 
healthcare professional groups, the HSE and various 
industry associations to gather their experience and 
perspectives about the reasons for shortages and 
the appropriate management of them.
– In light of potential shortages arising from the 
response of companies to the exit of the UK from 
the EU, we also began discussions with other 
regulatory authorities with a view to developing 
harmonised product information and joint 
packaging. There were bilateral meetings/contacts 
throughout the year between the HPRA and the 
MEB (Netherlands) and the MPA (Sweden) to discuss 
labelling issues and work sharing opportunities. 
Discussions are also ongoing with the UK in this 
regard. There is a general consensus that in so far as 
possible we should continue with joint labelling and 
maintain the close communication between both 
agencies.
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• We continued to monitor the numbers of unauthorised 
products notified to us through the exempt medicinal 
product scheme. One aspect of our approach to 
reducing the risks to patients is to actively seek new 
marketing authorisation applications for high-volume 
products currently being imported through this 
scheme. One application was received by year end 
and is being considered. It is anticipated that this will 
be assessed under an accelerated procedure.
• In November 2016, the Minster for Health requested 
the HPRA to provide scientific advice in respect of 
the potential medical use of cannabis. The HPRA 
convened an expert working group to assist with its 
review of this matter. The HPRA report – Cannabis 
for Medical Use: A Scientific Review – outlines the 
key findings and conclusions of the working group. 
Following approval by the Authority of the HPRA 
on 25 January 2017, the report was presented to 
the Minister for Health on 31 January and published 
on the HPRA website. The HPRA then commenced 
a series of engagements in respect of the report 
findings and met with a number of patient and public 
representatives. The HPRA also appeared before the 
Oireachtas Joint Committee on Health to discuss the 
report on 7 March.
 The Minister for Health endorsed the HPRA report 
and established the Cannabis Reference Group 
during 2017 to prepare clinical guidance and develop 
a national Cannabis Access Programme to enable 
access to cannabis for medical use. In conjunction with 
stakeholders, including the HPRA, the Department of 
Health is developing the Cannabis Access Programme 
and the Statutory Instruments to underpin the 
programme.
Authorisation and registration: Key figures
2015 2016 2017
Classification queries 80 49 34
Scientific advice 
 Lead in EMA scientific advice:
 National scientific advice (commenced in 2016)
39
--
51
13
47
6
Clinical trial applications 108 108 96
Voluntary Harmonisation Procedures (multinational clinical trials) 
 Lead
 Participating member state
8
15
8
22
5
14
New medicines applications for marketing authorisations 
 National
 Mutual recognition and decentralised RMS
 Mutual recognition and decentralised CMS
 Centralised Rapp/Co-Rapp/Peer reviewer
137
17
422
12
71
12
365
20
104
10
370
12
Traditional herbal medicinal products under the simplified registration scheme 7 9 4
Homeopathic medicines under the simplified rules scheme 0 1 2
Variations to marketing authorisations (Type IA, IB, II) 14,461 13,837 11,600
Articles 45 and 46 - Variations to Update Product Information 1 1 2
Renewals of marketing authorisations 322 351 248
Transfer of marketing authorisation holder 245 209 208
Parallel product authorisations 125 57 99
Manufacturers 95 103 111
Manufacturers of investigational medicinal products 52 55 52
Wholesalers 287 318 348
Registrations for active pharmaceuticals ingredients
 Manufacturers
 Importers
 Distributors
22
37
37
21
41
49
28
59
81
Brokers 1 3 9
Export certificates 1,646 1,274 1,375
Exempt medicines programme for notification of unauthorised medicine import 1,639,312 
packs
1,827,047 
packs
1,961,541 
packs
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Safety and Quality
• Under the SCOPE project (Strengthening 
Collaboration for Operating Pharmacovigilance in 
Europe) created to support pharmacovigilance in the 
EU following legislative requirements that came into 
effect in June 2012:
– There was collaboration with stakeholders 
concerning the distribution of joint DHPCs, and 
targeted communications to raise awareness of the 
availability of educational materials on the HPRA 
website.
– We engaged with IPPOSI, as part of its pilot Patient 
Education Programme specifically tailored for Irish 
patient communities, to provide medicines safety 
input for patient training materials. 
– Additional modalities were explored for 
communication of pharmacovigilance issues, 
including social media platforms, focused safety 
alerts to stakeholders and video sharing websites, 
while quality standards, ‘best practice’ and training 
materials were implemented.
• In anticipation of the changed reporting rules for the 
EU’s Eudravigilance database of adverse reactions:
– The HPRA’s own adverse reaction database was 
updated to ensure compliance with the new 
reporting standard. This was fully operational in 
October, ahead of the move to centralised reporting 
to the Eudravigilance in November, including an 
updated reporting process and training of all staff.
– Updates were given to stakeholders to facilitate 
appropriate and timely testing of the new standard 
and reporting arrangements, including through the 
Medicinal Products Newsletter and website updates 
and alerts.
• Adverse reactions reports assist the HPRA, in co-
operation with pharmacovigilance professionals in 
Europe and further afield, to look for new types of 
reactions or changing trends in reporting. Reports 
submitted to the HPRA in many instances arise 
from concerns occurring during observation of an 
unexpected and / or unwanted event, in the context 
of use of a medicine. They also include known adverse 
reactions, such as those described in the product 
information. This year:
– 4,402 adverse reactions reports were received 
associated with the use of human medicines. This 
represents a 35% increase in overall reporting rates 
compared with 2016. While there was already a 
legal obligation for marketing authorisation holders 
(MAHs) to report all serious adverse reaction reports 
of which they become aware to the HPRA, since 
22 November 2017 this requirement was extended 
to include non-serious reports. This change to 
reporting requirements largely accounts for the 
increase in the volume of reports received. 
Adverse Reaction Reports
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– In the context of the changed reporting 
requirements, 76% of all adverse reaction reports 
received by the HPRA in 2017 were reported by 
MAHs, with a further 1.5% reported in the context 
of ongoing clinical trials. It is important to note 
that these reports will have initially been notified to 
companies by healthcare professionals, patients or 
consumers. The remainder of the reports received 
(22.5%) were submitted directly to the HPRA by 
healthcare professionals and members of the public 
with almost half of these submitted through the 
HPRA’s online reporting system. 
– Medicines subject to additional monitoring 
accounted for 26% of the reports submitted.
– The medicines most frequently included in reports to 
the HPRA accounted for 78% of the adverse reaction 
reports received in 2017 (see table). It is important 
to note that the place of a medicine on this list 
cannot be taken as an indicator of safety or risk. The 
number of reports received cannot be used as a 
basis for determining the incidence of a reaction as 
neither the total number of reactions occurring, nor 
the number of patients using a medicine, is known.  
Suspect Medicine(s) /    
Class of Medicines
Number of 
Reports*
Antineoplastics, including 
immunomodulating medicines, monoclonal 
antibodies and endocrine medicines
1,854
Psycholeptic medicines 453
Anti-infective medicines, including 
antibacterials, antimycotics, antivirals and 
immunoglobulins
413
Vaccines 294
Medicines for the treatment of bone disease 193
Cardiovascular medicines, including 
antihypertensives and lipid lowering agents 166
Medicines used in Diabetes 155
Medicines used to treat Parkinson’s Disease 149
Antithrombotic medicines 136
Respiratory medicines 125
– Of the new adverse reaction reports received by the 
HPRA in 2017, 262 patients were reported to have 
died while on treatment. The table below outlines the 
medicines or class of medicines associated with the 
highest number of reports. In many of these cases, 
the patients had significant underlying illness and 
were treated with multiple medicines and/or surgery 
which may also have contributed to the outcome. 
In addition, many of these cases were influenced by 
disease progression or other complications unrelated 
to the medicine. The majority were associated with 
medicines subject to close monitoring, those used 
in the management of severe underlying medical 
conditions, in patient support programmes and 
special patient monitoring programmes.
Suspect Medicine(s) /    
Class of Medicines
Number of 
Reports*
Antineoplastics, including 
immunomodulating medicines, monoclonal 
antibodies and endocrine medicines
114
Psycholeptic medicines 31
Antithrombotic medicines 19
Analgesic medicines 16
Anti-infective medicines, including 
antibacterials, antimycotics, antivirals and 
immunoglobulins
15
Parenteral nutrition preparations 10
Cardiovascular medicines, including 
antihypertensives and lipid lowering agents 8
Respiratory medicines 6
Medicines for the treatment of bone disease 5
Radiopharmaceuticals for treatment of 
cancers 4
* Please note that in some cases treatment may have 
involved more than one medicine from the groups listed.
• The HPRA also plays a key role in monitoring the 
safety of medicines on the Irish market via our 
vigilance assessment and risk management activities. 
This incorporates our contribution to the work of 
the Pharmacovigilance Risk Assessment Committee 
(PRAC) at the EMA. During 2017, the HPRA:
– Continued our involvement in the work-sharing 
initiative for signal detection within the EU acting 
as lead Member State for the monitoring of 54 
nationally-authorised active substances. Serving 
as PRAC rapporteur, we were also responsible for 
the further management of any signals detected 
in relation to 42 centrally authorised medicines 
(containing 28 active substances / combination of 
active substances).  
– Participated in the EU periodic safety update report 
(PSUR) single assessment procedure, contributing to 
the evaluation of 941 PSURs and leading the single 
EU assessment for 29 of these procedures.
– Participated as a concerned Member State in 
13 newly initiated safety referrals seven of which 
reached a conclusion during the year.
– Contributed to the review of 154 risk management 
plans (newly approved or updated) submitted 
via national, mutual recognition, decentralised 
and centralised procedures. We also provided 
assessment input to 348 post authorisation safety 
study procedures (protocols, reports and other post 
authorisation safety-related measures).
• The inspections and audits programme focuses on 
ensuring industry compliance with relevant standards 
and legislation. This year, there were: 
– 106 good manufacturing practice (GMP) inspections 
conducted at sites that produce human medicines or 
active substances.
– 183 good distribution practice (GDP) inspections at 
wholesalers and distributors;
– 13 good clinical practice inspections;
– 4 pharmacovigilance inspections. 
• The HPRA’s risk based sampling and analysis 
programme is part of our monitoring of the quality 
and safety of medicines on the Irish market or which 
are manufactured in Ireland for export. It involves the 
analytical testing of products and / or examination of 
their packaging and labelling. A total of 288 samples 
were taken under the programme in 2017. This 
included:
– The examination of the packaging and labelling of 
136 medicines and other products available on the 
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Irish market. A total of 35 non-compliances were 
identified including Braille-related issues, non-
compliant packaging and labelling, and the absence 
of updated safety information. Appropriate follow-
up actions were taken in each case.
– Additionally, 128 medicines and other product 
samples for human use were sent for analytical 
testing during the past year. Although the majority 
of the samples tested were compliant with their 
specifications, a number of out-of-specification 
results were also obtained. The most frequent of 
these related to product appearance not being 
in accordance with the specification. Again, 
appropriate follow-up actions were taken in each 
case.
• The quality defect and recall programme investigates, 
on a risk basis, reports of suspected quality defects 
in medicines and in their related active substances. 
It also co-ordinates recalls from the Irish market. 
Quality defects pertaining to 650 medicines for 
human use were reported or identified in 2017. The 
risk classifications that were assigned, along with the 
corresponding figures for the previous two years, are 
outlined in the accompanying table.          
Year 2015 2016 2017
Critical quality defects 213 119 124
Major quality defects 218 331 196
Minor quality defects 301 382 327
Number of reports not justified 5 3 3
Total Number Quality Defects 737 835 650
As in previous years, companies (65%), including 
manufacturers, distributors and/or authorisation 
holders, and other competent authorities (27%) were 
the primary sources of received reports. 
• In certain cases, it may be deemed necessary to 
withdraw, or recall, medicines from the Irish market 
in order to protect public health. During the year, 
82 medicine recalls occurred representing a 59% 
decrease when compared to 2016 (when an unusually 
high number of recalls occurred due to distribution 
issues). Overall, the most common causes of recalls 
during 2017 were:
Cause of Recall Human 
Medicines
Erroneous distribution activities 11
Stability issues 11
Non-compliance with variations 7
Lack of sterility assurance 9
Other non-compliance with GMP 6
Non-compliance with SPC/printed artwork 5
Non-compliance with specifications 5
Adverse reactions or changes in benefit/
risk ratio 4
Primary/secondary packaging component 
issues 4
• One of the mechanisms used by the HPRA to aid 
continuity of supply to the market place in the event 
of a medicine shortage includes the granting of a 
temporary authorisation for a batch of a medicine 
known as a ‘batch specific request’. In 2017, there 
were 115 requests received.
• The HPRA monitors the general retail sale of consumer 
healthcare products in outlets such as grocery shops, 
health food shops and, where necessary, pharmacies. 
This year, 73 cases, some of which involved multiple 
products, were investigated. Of these,
– 34 related to the sale of medicines that did not carry 
a valid registration number or authorisation number 
for the Irish market. 
– 22 related to proactive monitoring of compliance 
of retailers in the sale of certain medicines with 
additional restrictions; and
– 17 related to the sale of products that had been 
incorrectly classified as non-medicines by those 
placing them on the market. 
 A total of 57 medicines that did not carry a valid 
registration or authorisation for the Irish market were 
removed from sale with 11 of these medicines subject 
to prescription control.
• Three regulatory compliance inspections were 
conducted at the premises of marketing authorisation 
holders to determine the level of compliance with the 
legal requirements for the marketing and advertising 
of medicines. 
• The advertising compliance programme monitors 
and reviews advertising and promotion activities by 
the industry for compliance with the legislation. This 
year 334 advertisements were reviewed, and non-
compliances, including both major and minor issues, 
were identified in 160 of these. In all cases, the HPRA 
oversaw the necessary corrective and/or preventative 
actions for those issues, where relevant. Eight 
advertisements were recalled. (The HPRA has published 
a standalone report available from our website which 
provides an overview of the main elements of the 
advertising compliance programme for 2017). 
• Under our enforcement programme:
– The HPRA detained 948,915 dosage units (including 
tablets, capsules and vials) of falsified and other 
illegal medicines last year compared to 673,906 
units in 2016 – an increase of more than 40%. 
The products detained, through both ongoing 
surveillance and targeted intelligence based 
operations, included anabolic steroids (47%), 
sedatives (23%) and erectile dysfunction medicines 
(13%). There was a significant rise in the number 
of anabolic steroids detained rising from 109,006 
in 2016 to 449,411 dosage units in 2017. The 
HPRA also took possession of 336,200 dosage 
units of expired medicines in order to arrange for 
their destruction in accordance with national waste 
legislation. Separately, a total of 3,866 enforcement 
cases were initiated, compared to 4,054 in the 
previous year.
– In one operation of particular significance, over 
60,000 vials labelled as containing anabolic steroids 
were detained as part of a joint operation carried 
out with An Garda Síochána and Revenue’s Customs 
Service at a number of locations in County Donegal. 
Other medicines, including human growth hormone 
and products indicated for erectile dysfunction, 
were also found. The total value of illegal medicines 
detained was estimated to be in excess of €2 million.
– We initiated six prosecution cases and issued six 
voluntary formal cautions. Prosecutions are taken 
where the HPRA considers that there is a significant 
risk to public health. The 2017 prosecutions related 
to the unauthorised supply of prescription medicines, 
including anabolic steroids and erectile dysfunction 
products. The HPRA also supports prosecutions 
brought by the Director of Public Prosecutions in 
relation to the illegal supply of medicines.
– The HPRA, in partnership with Revenue’s Customs 
Service and An Garda Síochána, detained over 
200,000 units of illegal prescription medicines in 
Ireland, valued at over €850,000, as part of the 
Interpol-coordinated Operation Pangea X. The 
products detained included significant volumes of 
anabolic steroids, sedatives and erectile dysfunction 
medicines. Nationally, the week-long operation 
also resulted in two arrests, the investigation of 38 
websites and eight social media pages being taken 
offline. Operation Pangea X was an international 
week of action across 123 countries to tackle the 
online sale of counterfeit and illicit medicines and 
highlight the dangers of buying medicines online.
Legislation and Regulation
• The new Clinical Trial Legislation, Regulation EU No 
536/2014, was originally intended to be implemented 
throughout the EU by October 2018 but this timeline 
has been deferred due to delays in building the online 
portal for applications at the European Medicines 
Agency. Notwithstanding these European delays, 
some national activities have been progressed during 
2017:
– We engaged with the Department of Health 
and HIQA regarding the implementation of the 
Regulation and the development of national 
legislation. 
– We developed a pilot scheme (for commencement 
in January 2018) for simultaneous submission of 
applications to both the HPRA and ethics committee 
which will enable preparation for implementation 
of the Regulation. Guidance and templates for 
sponsors were published in December.
– We actively participated in the European voluntary 
harmonisation project which is similar to the 
approval process for clinical trials under the planned 
new legislation (see page 13).
• From 9 February 2019, under the Falsified Medicines 
Directive, medicines must carry special safety features 
in the form of an anti-tamper device and a barcode 
containing ‘unique identifiers’ (including a serial 
number) to enable the authenticity of the pack to be 
checked prior to dispensing. This year:
– Updates in respect of the national implementation 
and introduction of these measures, including the 
establishment of the National Medicines Verification 
Organisation’s repository, were given to industry 
stakeholders at the HPRA’s Good Manufacturing 
Practice (GMP) and Good Distribution Practice 
(GDP) information days which took place on 7 and 8 
February. 
– The EU working group, led by the HPRA, on 
supervision of the national repositories of unique 
identifiers developed a work plan for the project 
with agreed outputs and timelines for completion. 
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• We participated in audit teams as part of the Joint 
Audit Programme (JAP) of GMP inspectorates 
of competent authorities. This also included the 
allied Joint Reassessment Programme (JRP) of the 
Pharmaceutical Inspection Co-operation Scheme 
(PIC/S).
Stakeholders and Partners
• As previously outlined (see page 14), the HPRA 
appeared before the Oireachtas Joint Committee 
on Health in early March along with officials from the 
Department of Health to discuss the report – Cannabis 
for Medical Use: A Scientific Review. The HPRA Chief 
Executive, who was accompanied by the Clinical 
Assessment Manager, outlined the report findings and 
recommendations which were finalised following input 
from an expert working group comprising relevant 
clinical experts and patient representatives. The HPRA 
representatives provided responses to a number of 
queries from the Committee members. 
 In May, the HPRA’s Director of Human Products 
Monitoring joined experts from the Department of 
Health, the Royal College of Physicians in Ireland 
and the HSE in addressing members of the Joint 
Committee on Health on the issue of vaccine uptake 
levels. Among the topics discussed were the huge 
positive public health impact of vaccination, how the 
safety of vaccines are monitored on an ongoing basis, 
and issues related to the fall in the numbers receiving 
the HPV vaccine in the recent past.
• As in recent years, the HPRA delivered a programme 
of presentations and talks at external stakeholder 
events such as meetings, seminars, conferences 
and training courses. These presentations provide 
stakeholders such as healthcare professionals and 
regulatory professionals with access to relevant, 
up-to-date information. In addition, a programme of 
presentations was delivered to undergraduate and 
postgraduate students studying courses related to 
the role of the HPRA. A full list of all presentations 
delivered during 2017 relevant to human medicines is 
provided in Appendix 2.
• Publications and Information 
– The Drug Safety Newsletter provides important 
safety information to healthcare professionals with 
hyperlinks to product information and other relevant 
documents on the HPRA and EMA websites. 
Seven issues of the newsletter were published and 
distributed to registered healthcare professionals, 
all of which are accessible from the HPRA website. 
A full index of topics covered during the past year is 
included in Appendix 3.
– Risk communications: 
• During 2017, 106 new or updated educational 
materials were approved by the HPRA in 
addition to 21 direct healthcare professional 
communications. 
• The PRAC monthly agendas, minutes, meeting 
highlights, notifications of safety reviews and 
signals were also made available via our website.
– There were a number of articles provided for 
inclusion in the monthly MIMs (Ireland) publication in 
addition to articles for the Irish Medicines Formulary. 
The full list of topics covered in these articles is 
included in Appendix 3. 
– The Medicinal Products Newsletter provides 
regulatory news and updates for those working in 
the pharmaceutical industry. Three editions were 
published on our website in 2017 and are available 
to download from the ‘Publications’ section. 
– Three new guidance documents relevant to human 
medicines were published in 2017 and are available 
to download from our website:
• Guide to Scientific and Regulatory Advice for GXP 
activities
• Guide to Clinical Trials Regulation (EU) No. 
536/2014 Pilot Project
• HPRA Brexit Guidance
• HPRA information seminars and training events 
provide regulatory guidance and updates to a range 
of stakeholders. Our programme of events in 2017 
included:
– The biennial good manufacturing practice (GMP) 
and wholesale distribution information days which 
were held on consecutive days in February and 
attracted a combined attendance of almost 650 
industry representatives.
– A GMP inspector training course, organised by the 
HPRA on behalf of PIC/S, which took place in Dublin 
from 23 to 27 October and was attended by 34 GMP 
inspectors from 17 countries.  
– An information day in November for stakeholders 
on the HPRA’s regulatory compliance inspection and 
advertising programmes. This was attended by over 
140 industry representatives.
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As the national competent authority for 
medical devices, the HPRA carries out a range 
registration, surveillance, monitoring and 
compliance activities. Our aim is to make sure 
that these products perform as intended and 
do not compromise the health and safety of the 
patient or the person using them.
Authorisation and Registration
• The HPRA is focused on ensuring effective and 
consistent designation and oversight of notified 
bodies at national and European level. In 2017, we:
– Continued our schedule of oversight of the 
notified body in Ireland based on ongoing 
assessment, surveillance and observed audits.
– Provided expert assessors to participate in four 
EU joint assessments of notified bodies based 
in other European countries. Since the scheme’s 
introduction in 2013, the HPRA has provided 
the highest number of expert assessors to this 
programme compared to other EU countries.
– Continued to provide leadership and support 
development of EU coordination of notified body 
designation and oversight by acting as the deputy 
chair for the EU Notified Body Operations Group 
(NBOG) and participated in the core EU Joint 
Assessment Coordination Group (JACG).
– Identified and prioritised development of systems 
and resources at national and EU level to allow, 
from November 2017 onwards, timely and 
effective designation of notified bodies required 
under the new EU Device Regulations (EUDR). 
• Supporting innovation and research of new 
technologies is a key strategic priority for the HPRA 
devices team. In 2017, this involved:
– The review of applications to conduct clinical 
investigations of medical devices in Ireland. The 
number of clinical investigations taking place 
continues to increase with nine new applications 
and six amendments to ongoing investigations 
received in 2017. The HPRA continues to focus on 
this area to ensure regulatory requirements and 
processes are clear to potential applicants.
– Organising a medical device innovation workshop 
in Galway hosted by the NUIG Clinical Research 
Facility in conjunction with the CURAM and 
BioInnovate facilities. The workshop was attended 
by over 50 innovators, researchers and clinicians. 
– Encouraging engagement during product 
development and innovation of medical 
technologies. During 2017, we met with 16 groups 
of innovators (13 preliminary and three pre-
submission meetings).
– Supporting the work of the HPRA Innovation 
Office by responding to around 40% of all queries 
received. 
– Presenting and participating in innovation sessions 
at a variety of conferences and workshops 
including the EuroPCR conference in Paris. 
• In 2017, the HPRA received 31 registrations of new 
organisations manufacturing self-declared medical 
devices in Ireland. A total of 362 new self-declared 
medical devices were also registered. Additionally, 
during the year we developed a comprehensive listing 
of economic operators within the medical device sector 
in Ireland (manufacturers, authorised representatives, 
distributors) to allow for better planning and 
coordination of our market surveillance activities.
Safety and Quality
• We continue to develop and reinforce our market 
surveillance activities, with particular emphasis on 
proactive rather than reactive actions. Of note in 2017:
– We launched a new lifecycle market surveillance 
strategy and planning mechanism to ensure 
continued safety and performance of devices 
throughout their lifetime. 
– We led or participated in various elements of both 
technical work packages of the EU Joint Action 
on Market Surveillance (JAMS) of medical devices 
initiative which is funded by the European Health 
Programme. In 2017, we hosted two workshops 
in Dublin and attended a further two in London 
involving delegates from 17 European countries 
with a view to:
• developing a process for coordination of EU level 
market surveillance issues;
• identifying a single secure communication 
platform for information sharing; 
• developing a process, best practices and training 
for joint manufacturer inspections; 
• developing a process for prioritisation of devices 
requiring common specifications.
– We continued our participation in the European 
COEN Joint Action 2014 on reusable and re-
sterilisable medical devices. In 2017, seven Irish 
based manufacturers were audited as part of the 
programme. One of these audits was conducted 
jointly with assessors from other Member States. In 
addition, the HPRA participated in one joint audit of a 
manufacturer in another Member State during 2017. 
– A total of 43 COEN notices were sent to the 
European network relating to medical device 
compliance concerns arising from HPRA activities 
while five information notices were published in 
relation to medical device issues. 
– There were 1,281 market surveillance cases* 
undertaken in 2017. The decrease in cases, when 
compared to 2016, is the result of a 26% decrease 
in the number of EU notifications received by 
the HPRA relating to notified body certificates.           
This decrease is likely as a result of the success 
of the joint assessment scheme. During 2017, 
the HPRA increased the number of other market 
surveillance cases by 24%, including technical file 
and clinical evaluation review cases. Such cases 
are more resource intensive and complex than 
certificate notification cases.
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* Please note that from the start of 2014, the HPRA 
changed the way we define market surveillance cases 
and so the figures in the graph have been adjusted to 
allow for comparison of annual figures.
• We continued to focus our vigilance activities during 
2017 on the areas of user reporting and dissemination 
of HPRA medical device safety communications. This 
included:
– The receipt and assessment of 2,339 medical 
device vigilance reports representing a 6% increase 
on 2016. 
– Of the incident reports notified to the HPRA, 12% 
came from users of medical devices. Manufacturers 
accounted for 62% of reports received in 2017 while 
30% came from other competent authorities. 
– There were 178 product removals conducted in 
Ireland during 2017. The HPRA also issued 89 
national competent authority reports. 
– Surgical devices, orthopaedic devices and infusion 
devices accounted for 42% of the total vigilance 
reports. Reports continue to be received relating 
to diagnostic imaging and radiotherapy devices. 
In addition, we continue to receive reports 
relating to revision procedures associated with the 
ASR Articular Surface Replacement and ASR XL 
Acetabular system manufactured by DePuy. During 
the year, we also continued development work on 
signal detection of medical device issues. 
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• As part of its market surveillance activities, the 
HPRA undertakes proactive and ‘for-cause’ audits 
of manufacturers, notified bodies and authorised 
representatives with the objective of monitoring 
compliance of devices emanating from Irish based 
organisations. During 2017, 22 audits were performed 
at both medical device manufacturers and authorised 
representative facilities, of which:
– three were for cause audits, one of which was in the 
US;
– eight were reactive audits based on vigilance / 
market compliance issues;
– sixteen were audits based on proactive market 
surveillance projects – including the EU joint action 
(COEN JA2014);
– two audits were conducted joint with other EU and 
international regulatory authorities.
Legislation and Regulation
• Following publication of two new European 
Regulations on medical devices in May 2017, the 
HPRA continued its work to help ensure an effective 
and timely implementation of these EU Device 
Regulations (EUDR) at national and European level. 
This included:
– Developing internal resources, procedures and 
systems to ensure notified body requirements could 
be applied at national level from November 2017. 
– Assisting the Department of Health in the 
development of relevant national legislation (S.I. No. 
547 of 2017) to nominate the HPRA as the National 
Competent Authority (NCA) for medical devices 
and the authority responsible for notified bodies in 
Ireland. 
– Preparing detailed information relating to the new 
requirements with respect to the need for national 
legislation, the timelines and impact on existing 
national legislation.
– Contributing to the European development of the 
secondary legislation required to enable notified 
body provisions to become applicable on time from 
26 November 2017. 
– Accepting nominations to represent Ireland at the 
newly established EU Medical Device Coordination 
Group (MDCG) and as part of the Regulatory 
Committee which decides on secondary legislation 
for the new EUDR. The first meeting of the MDCG 
took place in late November 2017.
– Participating in the EU steering group for 
development of the new European database (MDR 
EUDAMED) envisaged by the new Regulations. 
The HPRA also participated in a number of the 
associated technical working groups on certificate & 
registration, UDI and clinical aspects with a view to 
developing the system requirements and functional 
specifications.
– Participating in the development of Competent 
Authorities for Medical Devices (CAMD)’s Frequently 
Asked Questions on transition to the new legislation, 
which are now published on the CAMD website.
22 HPRA Annual Report 2017
Medical Devices
HPRA Annual Report 2017 23
• We continued to engage with the Department of 
Health throughout 2017 on policy and legislative 
issues. Of note, a national fee-based funding model 
for medical devices was implemented in January to 
recover the costs associated with our medical device 
activities. Fees were confirmed for all economic 
operators (manufacturers, authorised representatives 
and distributors) in Ireland. Further information 
and feedback received from the sector obtained 
during 2017 will be used to inform future revisions 
to the model which will be subject to further public 
consultation during 2018.
• The HPRA continues to play a significant role in 
the development of EU regulatory systems and 
mechanisms to promote coordination, cooperation 
and consistency. During 2017, we:
– Participated as a member of the Executive Group 
of the Competent Authorities for Medical Devices 
(CAMD) network. This group has successfully worked 
in partnership with the EU Commission over the last 
number of years to develop the regulatory system in 
Europe.
– Proposed the establishment of an Implementation 
Task Force (ITF) at the CAMD to identify priorities 
for EU work on implementation, provide a forum 
for discussion and consensus on interpretation of 
the new Regulations, and establish a mechanism for 
engagement with stakeholders on implementation. 
During 2017, the HPRA acted as interim chair 
for this taskforce, which published the European 
Implementation Roadmap in October. 
– Contributed to the design and delivery of training 
on notified body joint assessments to authority 
expert assessors at the EU Commission’s premises in 
Grange, Co. Meath.
– Continued to lead the work of the clinical 
investigation and evaluation working group, acting 
as the co-chair of the group along with the EU 
Commission.
• The HPRA continued to participate actively in 
initiatives to promote regulatory convergence and 
harmonisation of medical devices globally through 
the International Medical Device Regulators Forum 
(IMDRF). This involved:
– Participation in the IMDRF Management Committee 
as part of the European delegation (along with the 
EU Commission, France and Germany). 
– Continuing to act as the IMDRF secretariat for 
the National Competent Authority Report (NCAR) 
Exchange programme. We also participated in a 
number of different IMDRF working groups including 
the group on regulated product submissions (RPS) 
and medical device registries. 
– On behalf of the EU, we officially observed two 
Medical Device Single Audit Programme (MDSAP) 
assessments of manufacturing sites witnessing the 
performance of the auditing organisations. The 
HPRA also observed the assessment by a MDSAP 
consortium of an applicant auditing organisation.
– Contributing to briefings for the EU Commission for 
the purposes of the MDSAP Regulatory Authority 
Committee discussions and also encouraged 
discussions at EU level to further Europe’s future 
engagement in the programme. 
• We have an ongoing focus on horizon scanning and 
on developing our capabilities to effectively regulate 
new and emerging technologies. During 2017:
– Team members researched and attended training 
courses in a number of medical technology areas 
including software, cybersecurity and additive 
manufacturing.
– The Advisory Committee for Medical Devices 
(ACMD) established a new subgroup on medical 
device software and cybersecurity with a view to 
identifying challenges and regulatory / guidance 
needs. 
– The HPRA also assumed a leadership role in Europe, 
chairing the software classification subgroup of the 
EU classification borderline working group.
– We presented at a number of conferences and 
engaged with companies adopting additive 
manufacturing techniques (such as 3D printing) and 
were part of a cross-organisational horizon scanning 
project to examine and report on the regulatory 
aspects of additive manufacturing.
Stakeholders and Partners
• We continued to invest in stakeholder engagement 
and communication with medical devices stakeholders 
throughout 2017. This involved the promotion of 
direct reporting of incidents and medical devices 
issues by device users and members of the public. 
We also continued our engagement with health 
services and healthcare professionals to encourage 
reporting and raise awareness of the roles and 
activities of the HPRA. Work was undertaken with the 
HSE to identify mechanisms and identify appropriate 
individual contacts to facilitate dissemination of safety 
Human Medicines
information on medical devices to the relevant health 
services/users (designated person and vigilance liaison 
officers). We also continued to promote the adoption 
and communication of the HPRA step-by-step guide 
to user reporting which is targeted at healthcare 
providers. 
• The HPRA undertook a number of communication 
initiatives to raise awareness of the impact and 
requirements being introduced as a result of the new 
EUDR. During 2017, we:
– Established a dedicated section on HPRA website 
regarding EUDR. This incorporated stakeholder 
guidance and application forms for notified bodies 
to reflect the new requirements for designation to 
EUDR by the November timeframe.
– Published a dedicated newsletter and other 
information resources to raise awareness of 
specific aspects of the Regulations and its practical 
application. These included specific information 
leaflets targeting medical device innovators and 
also the cosmetic industry (given the inclusion under 
the new device Regulations of certain aesthetic 
products).
– Contributed to the development and actively 
participated in two European stakeholder days on 
the new EUDR hosted by the EU Commission and 
CAMD. 
– Provided briefings, advice and workshops on the 
new Regulations to a range of different stakeholders 
including notified bodies and distributors. 
• Throughout the year, we engaged in ongoing 
strategic, operational and communication initiatives 
on a bilateral and multilateral basis with European 
and international authorities, and the EU Commission. 
We also further developed our bilateral partnerships 
with a number of those authorities. In addition, we 
participated in operational and strategic discussions 
on developing cooperation between the CAMD and 
the Heads of Medicines Agencies (HMA) networks.• 
The HPRA continues to deliver a programme of 
presentations and talks at a range of external 
stakeholders. A full list of all presentations related to 
the regulation of medical devices that were delivered 
during 2017 is provided in Appendix 2.
Medical Devices: Key Figures
Year 2015 2016 2017
Lead Competent Authority role 
on specific vigilance issues
74 98 89
NCARs and vigilance related 
communications 
79 116 96
Vigilance cases received/opened 2,140 2,242 2,339
Field safety notices uploaded 474 476 519
Medical device safety notices 33 46 44
Medical device targeted 
healthcare professional 
communications
11 33 23
NCARs managed as IMDRF 
NCAR secretariat
- 18 8
COEN reports (market 
surveillance and vigilance) to EU 
network
12 45 44
Medical device information 
notices
3 0 5
Market surveillance cases 
(unadjusted)
324 335 411
Notifications relating to notified 
body certificates
959 959 844
Classification requests 54 35 51
Compassionate use applications 3 5 5
Medical device free sale 
certificates
2,601 2,122 2,371
Medical device queries received 459 477 496
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Blood, Tissues 
and Organs
The HPRA is responsible for monitoring 
the safety and quality of blood and 
blood components, and of tissues and 
cells. Along with the HSE, we are joint 
Competent Authority for organs intended for 
transplantation.
Authorisation and Registration
The authorisation of blood establishments, tissue 
establishments and organ procurement organisations 
/ transplantation centres permits those facilities to 
carry out specified activities. The total number of 
authorisations in place at year end for the past five 
years is presented by category in the accompanying 
table. 
Number of 
Authorisations
2013 2014 2015 2016 2017
Blood 
establishments
4 4 3 3 3
Tissue 
establishments
23 24 24 25 25
Organ 
procurement/
transplantation 
0 0 4 4 4
Safety and Quality
• Following collaboration with the National 
Haemovigilance Office (NHO), we submitted an 
annual report of serious adverse reactions and 
events to the EU Commission during 2017. The 
report reflected information received by the NHO in 
2016 and included information on 61 serious adverse 
reactions and 152 serious adverse events which met 
the mandatory legislative reporting requirements.
 
• We also submitted an annual report on serious 
adverse reactions and events associated with tissues 
and cells to the EU Commission during 2017. The 
report reflected information received in 2016 and 
consisted of some 112 reports, 103 of which met the 
legislative reporting requirements, including seven 
serious adverse reactions and 96 serious adverse 
events.
• The Joint Action on Vigilance and Inspection for the 
Safety of Transfusion, Assisted Reproduction and 
Transplantation (VISTART) promotes and facilitates 
the harmonisation of inspection, authorisation 
and vigilance systems in the EU for blood, tissues 
and cells used in transfusion, transplantation and 
assisted reproductive technology. As part of the 
HPRA’s contribution to VISTART activities, we are 
leading Work Package 9 which involves a voluntary 
programme of inter-member state inspection 
systems auditing. Consequently, we carried out a 
pilot audit in Q3 using tools developed under this 
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work package. In Q4, we also conducted an audit of 
the relevant Latvian authority as part of the pilot phase 
of the VISTART project.
• We continued to liaise with the HSE lead and 
colleagues from Organ Donation and Transplant 
Ireland (ODTI) in relation to our respective roles under 
EU and national legislation on the Quality and Safety 
of Human Organs intended for Transplantation. During 
2017, this included:
– The exchange of relevant information on serious 
adverse reactions and events. During 2017, the 
HPRA received 13 reports of serious adverse 
reactions and events associated with organ donation 
/ transplantation;
– The ongoing review of procedures and guidance 
incorporating the finalisation of updates to the 
report form which were completed by year end;
– The submission of proposals to the OTDI in 
respect of updating the framework for quality and 
safety. 
• As part of our regulatory role, the HPRA inspects 
relevant establishments, organisations and centres 
to monitor compliance with applicable EU guidelines 
on the quality and safety of blood, blood products, 
tissues and cells, and human organs intended for 
transplantation. Our inspection programme in 2017 
consisted of:
– 19 tissue establishment inspections of which four 
were non-routine; 
– 7 routine inspections of blood establishments; and 
– 1 routine inspection of an organ establishment.
Legislation and Regulation
• As part of our ongoing contribution to the review 
of relevant legislation, we provided feedback to the 
Department of Health on draft SIs for transposing EU 
Directives on coding and import for human tissues and 
cells. 
• In relation to assisted human reproduction, we 
engaged with the Department of Health during 
2017 to discuss the development of assisted human 
reproduction legislation including the proposed 
regulatory agency. We also engaged in respect of the 
commencement of parts 2 and 4 of the Children and 
Family Relationships Act.
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Veterinary  
Medicines
Our role is to grant licences for veterinary 
medicines subject to a review of their safety, 
quality and effectiveness. We continuously 
monitor their use in animals once they 
become available on the market in addition to 
authorising clinical field trials and inspecting / 
licensing manufacturing sites.
Authorisation and Registration
• There are a number of routes through which a 
veterinary medicine can be authorised by the HPRA. 
These include the national procedure, the mutual 
recognition procedure (MRP) and the decentralised 
procedure (DCP). The following applications were 
issued by the HPRA during 2017: 
– 10 new national applications; 
– 75 new applications made under the DCP; 
– 28 new applications made under the MRP. 
 We acted as reference (lead) Member State for the 
assessment of one of the MRPs and 30 of the DCPs. 
We also issued five applications as RMS under the 
repeat use procedure.
 The centralised route administered by the EMA is 
another mechanism whereby veterinary medicines can 
be authorised in Ireland. In 2017, the HPRA issued 16 
cases as rapporteur or co-rapporteur for veterinary 
medicines. An additional 18 new medicine applications 
were issued through the centralised route where we 
were neither the rapporteur nor co-rapporteur.
 By end of year, there was a record total of some 1,700 
veterinary medicines authorised for the Irish market.
• During 2017, the HPRA acted as co-ordinator for 
three requests under the EMA scientific advice 
procedure.
• Medicine shortages continue to be an issue for 
many veterinary practitioners tasked with treating a 
range of different species and conditions. Problems 
of non-availability can arise from a number of issues 
and different solutions are needed depending on the 
issues involved. During 2017:
– We conducted planned twice yearly reviews 
of AR18 and AR16 lists. The HPRA strategy 
is to review incoming requests and seek Irish 
authorisation where practicable.   
– We carried out gap analysis and prioritised 
applications linked to shortages.  
– Meetings were held with the Department of 
Agriculture, Food and the Marine to discuss 
shortages related issues. There was agreement to 
develop an inter-departmental process in respect 
of potential shortages arising from Brexit. 
– Communicated and met with applicants regarding 
transfer of reference member state (RMS) to 
Ireland. We also revised the relevant procedure 
and established a register of products for transfer.
– We worked closely with EU competent authorities 
to enable the use of common packs and carried 
out a survey to explore dual labelling interest in 
other Member States. 
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• Authorisation and registration: Key figures
Year 2015 2016 2017
Classification enquiries 21 16 11
Clinical trials 0 1 2
New centralised as (co-)rapporteur 11 11 16
New MR/DCP as RMS 15 14 30
New MR/DCP as CMS 93 78 44
New homeopathic applications 6 0 3
New national applications 5 8 8
Renewals, national and MR 88 100 108
Variations, national and MR 1431 1341 1366
Manufacturers of veterinary 
medicines 25 24 20
Export certificates 99 155 111
Safety and Quality
• The operation of a national pharmacovigilance 
system for veterinary medicines is dependent on the 
submission of reports by veterinarians, pharmacists, 
licensed merchants and others involved in dispensing 
or using the medicines concerned. These reports may 
be submitted either directly to the HPRA or to the 
companies marketing the medicines. The companies, 
in turn, must relay the data to the HPRA.
 Over the course of 2017, we received 397 national 
reports of suspected adverse events to veterinary 
medicines with the vast majority of reports, as in previous 
years, received from pharmaceutical companies. 
• We evaluated 630 periodic safety update reports 
(PSURs) which incorporated the assessment of 
individual medicines on the market in Ireland as well as 
a work-sharing initiative where we led, or contributed 
to, the assessment of a class of veterinary medicines 
for the European Union. 
• Containment of the development of antimicrobial 
resistance (AMR) is essential for public and animal 
health. Our work in this area includes the collection 
of annual information on the sale of veterinary 
antibiotics from each marketing authorisation holder. 
This information, which is included in the European 
Surveillance of Veterinary Antimicrobial Consumption 
(ESVAC), is important as it allows us to benchmark our 
usage rate against those of our European neighbours 
and to follow any developing trends. The data show 
that due to a variety of factors there are significant 
fluctuations in sales annually and, consequently, that a 
clear trend is not identifiable. 
Veterinary antibiotic use 2012 2013 2014 2015 2016
Tonnes sold 97.4 99.1 89.4 96.9 103.4
 Additionally in 2017, we continued our participation 
in the National Interdepartmental Antimicrobial 
Resistance Consultative Committee which in 
October published ‘Ireland’s National Action Plan on 
Antimicrobial Resistance 2017-2020’. 
• The analytical testing of products is a key component 
of the HPRA’s risk based sampling and analysis 
programme. A total of 31 samples of veterinary 
medicines were taken under the programme in 2017 
and all were subject to laboratory testing. Although 
the majority of the samples tested were compliant with 
their specifications, a number of issues, such as the 
crumbling of tablets, were noted. Appropriate follow-
up actions were taken as necessary.
• We investigate, on a risk basis, reports of suspected 
quality defects in medicines and active substances, 
and co-ordinate subsequent recalls from the Irish 
market where necessary. There were 48 quality defects 
pertaining to medicines for veterinary use reported 
or identified in 2017. The risk classifications that were 
assigned, along with the corresponding figures for the 
previous two years, are outlined in the accompanying 
table.          
28 HPRA Annual Report 2017
Veterinary Medicines
500
450
400
350
300
250
200
150
100
50
0
Adverse Event Reports
27
1
2013
30
0
2014
43
5
2015
33
7
2016
39
7
2017
HPRA Annual Report 2017 29
Year 2015 2016 2017
Critical quality defects 1 7 5
Major quality defects 8 12 13
Minor quality defects 25 22 30
Number of reports not justified 1 0 0
Total Number Quality Defects 35 41 48
 Companies, including manufacturers, distributors and/
or authorisation holders, accounted for 64% of the 
reports received with the balance received from other 
competent authorities. 
 In certain cases, in order to protect animal and / or 
public health, it is deemed necessary to withdraw, or 
recall, a veterinary medicine from the Irish market. In 
2017, seven recalls of medicines occurred which was 
one less than the previous year. Of these, three were 
recalled due to stability issues.
• Our inspections and audits programme focuses on 
ensuring industry compliance with relevant standards 
and legislation. In 2017, there were: 
– 12 good manufacturing practice (GMP) inspections 
conducted at sites that produce / test veterinary 
medicines;
– 2 pharmacovigilance inspections.
Legislation and Regulation
• We continued to engage with the Department of 
Agriculture, Food and the Marine in respect of the 
proposed new EU veterinary medicines legislation. 
Meetings were held to review the proposals and we 
presented feedback on each Commission revision. We 
also met before year end to consider the European 
Council discussions on the new legislation. The 
Department participates at Council meetings.
Stakeholders and Partners
• As part of our ongoing stakeholder engagement, in 
2017:
– We conducted a survey during Q2 in respect of 
outgoing MR/DCP applications to determine 
stakeholder perceptions of the HPRA‘s service levels 
and performance, and to assess their communication 
needs and expectations. Analysis of the results 
were completed by year end and the findings will 
be used to inform future service provision and 
communications.  
– We held meetings with a number of stakeholders 
during the year as part of our review and audit 
of the current level of national regulatory and 
scientific advice provision at each stage of product 
development.
– We are committed to participating in activities that 
promote pharmacovigilance reporting, in particular 
with respect to food-producing species. During 
the year, we developed a training proposal and 
submitted a draft training module to a third level 
institute for review and consideration. 
– As part of our commitment to enhance our 
stakeholder communication on safety issues, we 
developed and published a number of safety notices 
on our website in relation to vaccine shortages 
and topics including euthanasia, zinc oxide and 
monitoring of medicines.  
• Throughout 2017, we continued our involvement 
across the EU regulatory network which includes active 
participation at the EMA and the HMA. Of particular 
note, Dr David Murphy continued to serve as Chair 
of the EMA’s Committee for Medicinal Products for 
Veterinary Use (CVMP) following his election in 2016. 
• As in recent years, we delivered a programme of 
presentations to veterinarian students and veterinary 
nursing students on the role of the HPRA and the 
promotion of veterinary pharmacovigilance. We also 
presented at a number of industry stakeholder events. 
A full list of all presentations delivered during 2017 is 
provided in Appendix 2. 
• We continued during 2017 to publish relevant content 
in our Medicinal Products Newsletter. This newsletter 
provides updates for those working in the veterinary 
medicines sector on Irish and European legislation, 
new / revised HPRA regulatory publications and 
stakeholder events such as information days. Three 
editions were published on our website in 2017 and 
are available to download from the ‘Publications’ 
section.
 We also contributed a number of articles to the 
Veterinary Ireland Journal and the It’s Your Field 
publication. Details are included in Appendix 3.
Veterinary Medicines
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The HPRA is the competent authority in 
Ireland responsible for the implementation 
of EU legislation (Directive 2010/63/EU) for 
the protection of animals used for scientific 
purposes.
Authorisation and Registration
• The HPRA carries out evaluations of applications 
for the authorisation of research establishments 
and projects in addition to evaluating applications 
from individuals to allow them to conduct 
procedures or euthanasia of animals. As shown in 
the accompanying table, there was an increase in 
both the total number of individuals and projects 
authorised in 2017. Please note that the higher 
level of individual authorisations during 2013 and 
2014 was due to the legal requirement for existing 
establishment personnel to apply for individual 
authorisations, which are valid for five years, before 
the end of 2014. 
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Individuals         Projects
• In October, we published the fourth annual statistical 
report on the use of animals for scientific purposes 
in Ireland. The HPRA is required to collect and make 
publicly available, on an annual basis, statistical 
information on the use of animals in procedures, 
including information on the actual severity of the 
procedures.
Authorisation and registration – Key 2017 figures:
Year 2017
Individual authorisations 319
Project authorisation 125
Individual amendments 74
Project amendments 186
Establishment renewals 22
Safety and Quality
• During 2017, there were 33 inspections completed, 
of which 18% were unannounced, to monitor animal 
welfare standards and compliance with legislation. 
This total incorporated 25 establishment authorisation 
inspections and eight compliance inspections.
• One of the HPRA’s responsibilities in respect of 
scientific animal protection is to grant permission to 
rehome animals if certain criteria are met that protect 
and provide for the animal’s overall well-being. Early 
in 2017, we approved a pilot rehoming scheme for 
a group of dogs from Charles River Laboratories as 
a result of the closure of a facility in County Mayo. 
Following the positive outcome of the pilot, when a 
number of dogs were effectively rehomed through 
animal welfare organisations, the rehoming scheme 
was subsequently extended. It was concluded after 
the successful rehoming of 342 dogs and 249 cats 
confirming it as one of the largest projects of its kind 
ever undertaken. 
Stakeholders and Partners
• In May, in co-operation with the Health Research 
Board and Science Foundation Ireland, we hosted a 
3Rs conference in Croke Park, Dublin. The conference 
presented over 200 delegates with information 
and recommendations on how to apply the 3Rs to 
research with the aim of improving animal welfare and 
achieving better science. 
• We published and disseminated three regulatory 
updates to provide stakeholders with the latest news 
and guidance from the HPRA, with information on 
education and training, and with information and best 
practices in respect of the 3Rs and compliance with 
the legislation.
• In December, we delivered a Laboratory Animal 
Science and Training (LAST) lecture in relation to the 
legislative and regulatory aspects of scientific animal 
protection. 
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LASA/IAT/VCI CPD credits available
Discounted rates available for multiple attendees. 
For more information, go to www.hpra.ie
• Learn how to apply the 3Rs to your research, improving welfare and achieving better science
• Exciting program packed with 3Rs experts, including speakers from RSCPA, NC3Rs and UFAW
3Rs Conference
Replace
Refine
Reduce
WHEN: 17 May 2017
WHERE: Croke Park Conference Centre, Jones’ Rd, Dublin 3
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•  Exciting program packed with 3Rs experts, including speakers from RSCPA, NC3Rs and UFAW
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Authorisation and Registration
• Import, export and holding of controlled drugs (for 
legitimate purposes) are subject to licensing. The 
Department of Health is the licensing authority while 
the HPRA handles the administrative aspects of the 
application and licensing process. Licensing activity 
consists primarily of export and import licences, and 
letters of no objection. Data for the past five years 
are outlined in the accompanying graph.
• The HPRA is the licensing authority for precursor 
chemicals. These are subject to different licensing 
requirements, dependent upon specific categories. 
The following table shows the licensing activity since 
2013.
Precursor Chemicals 
Licensing Activity 
2013 2014 2015 2016 2017
Total 27 46 32 16 23
Legislation and Regulation
• Following commencement of the Misuse of Drugs 
(Amendment) Act 2016 on 4 May 2017, changes 
were made to the requirements for controlled 
drug import and export licences. All necessary 
adjustments to HPRA procedures and forms were 
subsequently implemented.
Stakeholders and Partners
• Prior to the commencement of the new legislation, 
we communicated with relevant stakeholders to 
remind them that a number of substances that 
were not previously controlled would now fall 
under the scope of the Misuse of Drugs framework. 
We published the relevant details in the HPRA’s 
Medicinal Products Newsletter in January and this 
was followed by the dissemination of an e-mail 
update in April. Companies were advised to review 
products handled to ascertain any impact of the 
proposed changes and to update procedures and 
authorisations where necessary.
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Cosmetic 
Products
The role of the HPRA is to regulate the 
manufacture, sale and supply of cosmetic 
products in Ireland. We identify and address 
cosmetic product quality and safety issues, in 
conjunction with the HSE, so that a cosmetic 
product will not compromise the health and 
safety of the consumer or the person applying 
the product. 
Authorisation and Registration
• During 2017, we issued 174 cosmetics free sale 
certificates which may be required by companies 
exporting products to third countries. 
Safety and Quality
• As part of our proactive market surveillance activities, 
we conducted three inspections of cosmetic 
distributors to assess compliance with the Cosmetics 
Regulation. Distributors were informed of any non-
compliances identified and requested to implement 
corrective actions.
• Our reactive market surveillance includes 
investigation of quality-related complaints 
(compliance cases), reports of adverse events 
relating to the use of cosmetics (vigilance cases) 
and serious risk alerts received from other countries 
(RAPEX).  In total, there was 312 reactive surveillance 
cases initiated during 2017.
Stakeholders and Partners
• We developed a cosmetic products information 
pack which was published in March 2017 to guide 
stakeholders through placing a cosmetic for sale on 
the market and to provide an easy-to-use checklist 
to help ensure all regulatory requirements were 
met before placing a cosmetic on the market. 
This initiative was undertaken as a result of direct 
feedback from stakeholders in 2016.
• We hosted three regulatory information seminars 
in Leitrim, Limerick and Dublin during October to 
provide cosmetic stakeholders with useful, up-to-
date information on their responsibilities under the 
Cosmetics Regulation. Given that many attendees 
were small businesses, we invited a member of the 
Local Enterprise Office to speak at each event also. 
These evening events were well attended and the 
feedback from stakeholders was that the information, 
which included printed copies of the information 
pack, was relevant and well presented.
• In addition, we launched a media information 
campaign in December to raise awareness among 
consumers of the dangers presented by counterfeit 
cosmetics in the run up to the Christmas period. The 
information was published by both print and online 
media and we participated in a number of national 
and regional radio interviews. Consumers were 
informed on how to spot a counterfeit cosmetic and 
of the risks these products can pose.
HPRA Annual Report 2017 33
34
Other Regulatory 
Programmes
HPRA Annual Report 2017
Inspections, Audits and Market 
Compliance
• The Joint Audit Programme (JAP) is a key element of 
the quality system adopted by good manufacturing 
practice (GMP) inspectorates in Europe and aims 
to ensure consistency of GMP standards and a 
harmonised approach throughout Europe. 
– A positive JAP evaluation of the HPRA was carried 
out from the 15 to 19 May by GMP inspectors 
from Austria, France and Iceland, and an auditor 
from the Commission’s Directorate General (DG) 
for Health and Food Safety. Our GMP inspections, 
manufacturers’ licensing, quality defects and recall 
programme, and sampling and analysis systems 
were examined in addition to the legislation for 
both human and veterinary medicines and our 
overarching quality management system. As part 
of the assessment, the conduct of a full GMP 
inspection by the HPRA was observed by one 
member of the audit team. 
– Also in 2017, the HPRA led two JAP evaluations 
of the GMP compliance programme of other 
member states. One was at the State Institute for 
Drug Control (SIDC), the competent authority for 
human medicines in the Slovak Republic, while the 
other was at the Agency for Medicinal Products 
and Medical Devices of the Republic of Slovenia 
(JAZMP).
• The successful completion and positive outcome of 
the HPRA’s JAP evaluation validates the strength of 
our processes and procedures for inspection and 
quality defect management. Of particular note, 
our audit was observed by the US FDA as part of 
its review of the equivalency of HPRA systems in 
relation to the US/EU mutual recognition agreement 
(MRA) on GMP inspections. A detailed data package 
was also prepared and presented to the FDA for its 
consideration as part of competency assessment. 
The FDA subsequently confirmed that the HPRA has 
the capability, capacity and procedures to carry out 
GMP inspections at an equivalent level. As a result, it 
is anticipated that Ireland will be included on the list 
of recognised member states under the MRA during 
2018 and from that point forward the FDA can rely 
on HPRA inspections to replace its own inspections.
• Other EU contributions included leading on: 
– the development of a new risk assessment tool 
for the selection of medicinal products and active 
substances for surveillance testing; 
– a new risk-based tool to support inspection and 
surveillance relating to heparin manufacturers and 
their related products; and 
– the development of a communication tool-kit for 
the Official Medicines Control Laboratory (OMCL) 
Network. 
• We completed a pilot project, which commenced 
in 2016, on advertising compliance with regard 
to advertising advisory boards. A report on the 
outcome of this project will be finalised in early 
2018.
Innovation Support
• Supporting innovation is one of the HPRA’s five 
strategic goals. This is in recognition of the pace of 
development of new health products, technologies 
and platforms and the resulting potential to provide 
huge benefits for patients. However, the changes 
being brought about by innovation can also present 
challenges for the regulatory model as it is currently 
constructed. Our actions under this theme during 
2017 included the following:
– This was the first full year of activity for the HPRA’s 
Innovation Office which provides regulatory 
support and advice to individuals, academics, 
small and medium enterprises, pharmaceutical 
and medical device companies, and other groups 
who are developing innovative health products 
or technologies. A total of 38 of queries were 
received, mainly from SMEs and academia, with the 
majority relating to medical devices, medicines and 
borderline products. 
– A new formal in-house horizon scanning process 
was developed during 2017 to enable the HPRA 
to identify, at an early stage, developments and 
events that may require discussions at an EU level 
and potential changes to the regulatory framework. 
There may also be a resulting need to develop 
knowledge or expertise within the HPRA or to 
identify and recruit external experts. The first report 
produced by the horizon scanning group focused 
on additive manufacturing / 3D printing. A cross-
organisational group is now moving ahead with the 
implementation of the report recommendations. 
Linked to this initiative, the EU Innovation Network 
adopted a HPRA proposal concerning a roadmap for 
the establishment of common approach to horizon-
scanning. 
– The HPRA played a leading role in setting up 
an innovation project among members of the 
International Coalition of Medicines Regulatory 
Authorities (ICMRA). Following an initial survey, 
we prepared a project proposal that identified 
three work streams that will be the focus of future 
activities. One of the work streams, focusing on 
outcomes of horizon scanning, is jointly led by the 
HPRA and the EMA. 
– The HPRA provides a classification service to 
stakeholders for products which are on the 
borderline between medicines and medical devices 
and other categories such as cosmetics and food 
supplements. This will generally determine the 
legislation under which a product be regulated. 
During 2017, an integrated medicines and medical 
devices classification system for handling requests 
from stakeholders was developed to optimise the 
consistency of HPRA decision-making process. This 
will be implemented from Q1 2018. 
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Outreach and 
Engagement
The HPRA is committed to a strategic focus on 
outreach and engagement with key partners 
and stakeholders so as to enhance and 
maximise the effectiveness of the regulatory 
system. 
• In our outreach activities to support innovation 
developments in Ireland: 
– The HPRA organised an innovation day in May in 
the O’Reilly Institute in UCD. Over 260 attendees 
registered for the event from various backgrounds 
including academia, research networks, SMEs, 
other agencies with an interest in innovation and 
the pharmaceutical and medical device industries. 
Feedback subsequent to the event was very 
positive with stakeholders welcoming the HPRA’s 
desire to reach out and engage with innovators. 
Extensive tweeting of @TheHPRA Twitter account 
during the day helped promote the HPRA to new 
audiences.
– We participated in a number of external events 
to promote our supports to innovation including 
the Medtech Innovation Showcase at the ‘Med in 
Ireland’ event organised by Enterprise Ireland. This 
was attended by over 250 international companies, 
70 indigenous medtech companies and a number 
of other organisations focused on encouraging 
innovation in Ireland. We also exhibited and 
presented at the ‘Taking Care of Business’ event 
organised by the Department of Business, 
Enterprise and Innovation in November. In the 
same month, the HPRA’s innovation office exhibited 
at the SME Information day held at the EMA. 
– As part of outreach activities, we met with a 
variety of research bodies including the RCSI, the 
Regenerative Medicine Institute (REMEDI) and the 
Centre for Cell Manufacturing Ireland (CCMI). We 
also met with Science Foundation Ireland (SFI) and 
the National Institute for Bioprocessing, Research 
and Training (NIBRT) to discuss HPRA supports for 
innovation and areas of common interest 
– The HPRA is an active participant of the 
Pharmaceutical Education and Research with 
Regulatory Links (PEARRL) programme. As part 
of this initiative, four early stage researchers 
were given the opportunity to work within the 
medicines assessment area for three months 
so that they could get an understanding of the 
regulatory process. As part our participation in this 
programme, we were involved in organisation of 
a regulatory science symposium in Cork in June 
2017 entitled ‘Regulatory Support of Innovation in 
the Pharmaceutical Industry’.
– Staff also presented on horizon-scanning and 
innovation supports to the National Centre for 
Pharmacoeconomics and industry association 
meetings. 
– Additionally, we commenced a review of the 
HPRA’s contribution to external education 
programmes which incorporates consideration of 
the most appropriate formats for future activities. 
We met with APPEL (Affiliation for Pharmacy 
Practice Experiential Learning) to discuss 
involvement in education of pharmacists.
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• Stakeholder communications and engagement:
– The HPRA was pleased to participate as one of a 
number of education partners working with the 
Irish Platform for Patient Organisations, Science 
& Industry (IPPOSI) to deliver a Patient Education 
Programme in the area of health innovation. The 
programme, which was specifically tailored for Irish 
patient communities, was piloted from September 
2017 to March 2018 based on a ‘blended learning’ 
approach consisting of e-learning and face-to-
face sessions. The HPRA module, which ran for 
five weeks during November and December, was 
focused on regulatory affairs, medicines safety 
and pharmacovigilance. The programme students 
completed three modules in total with the 
additional modules focused on clinical trials and 
health technology assessments.
– The HPRA’s first ever national information 
campaign was launched in September 2016. The 
campaign, which incorporates radio, digital and 
print advertising, was repeated in 2017 during 
March / April and again in October. The focus of 
the HPRA adverts is to highlight the importance 
of the safe use of medicines as well as medication 
adherence in general. Our key message to 
members of the public is to take care when taking 
medication and specifically to be aware of and 
read the information and directions for use that 
come with every medicine. 
– Throughout the year, we continued our media 
communications programme to proactively 
communicate important safety messages and 
to build awareness of the role of the HPRA. We 
issued 25 press releases and website statements 
concerning safety and regulatory issues to 
ensure consumers, healthcare professionals 
and other stakeholders received timely and 
accurate information and advice. In a number 
of instances, these communications resulted in 
national and regional media interviews with a 
HPRA spokesperson. In addition, we responded to 
more than 500 initial and follow-up queries from 
national, local and specialist media during the 
year.
– The HPRA website – www.hpra.ie – is a key 
communications channel and we continuously 
monitor and analyse key visitor and usage 
statistics. Among the key findings from 2017 were: 
• Almost 314,000 unique visitors accessed 
our website during the past twelve months 
representing a more than 10% increase 
compared to 2016. 
• There were in excess of 770,623 visits in total 
throughout the year. 
• Of those who accessed the site, close to 20% 
were new or first time users. 
– The @TheHPRA Twitter account was launched in 
late 2016 as a tool to support our communications 
activities and direct additional traffic to the HPRA 
website. We continued to develop our Twitter 
activity during 2017 and by year end we had 
secured more than 800 followers. Among the 
highlights was our participation in an EU-wide 
social media campaign to promote the reporting 
of suspected side effects from medicines. This 
campaign was supported by a range of patient 
organisations and other national health agencies.  
• HPRA information seminars and training events: 
 These events provide regulatory guidance and 
updates to a range of stakeholders. The HPRA also 
partners with other regulatory organisations to co-
host relevant sessions. During 2017, we hosted the 
following events:
– VISTART Workshops, 1 – 2 February and  
30 – 31 March 
– GMP Information Day, 7 February 
– GDP Information Day, 8 February 
– JAMS Workshops, 10 – 11 April and 30 November 
– 3Rs Information Day, 17 May  
– Innovation Day, 25 May  
– Brexit Stakeholder Meeting, 31 August 
– Cosmetic Information Days: 11 October in 
Carrick-on-Shannon, 12 October in Dublin and 19 
October in Limerick
– Biosimilar Information Seminar, 18 October 
– PICs Training, 23 – 27 October (NIBRT)
– Working Group of Quality Managers and Working 
Group of Communications Professionals, 27 – 29 
November  
– EMA QWP Assessor Training, 4 – 5 December
• European and international initiatives: 
– We continued providing technical assistance to the 
Zambia Medicines Regulatory Authority with our 
consortium partners, and issued a ‘Health Systems 
Strengthening Programme for Zambia’ report in 
June.
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– In early 2017, the World Health Organisation 
(WHO) announced Ireland as the location for the 
next International Conference of Drug Regulatory 
Authorities (ICDRA) which takes place in September 
2018. This WHO global event provides regulatory 
authorities with a unique forum to meet and discuss 
ways to strengthen global collaboration in the area 
of medicines’ regulation. Throughout the year, the 
HPRA progressed planning and preparation for the 
five-day conference which is expected to attract 
more than 300 delegates from up to 100 countries 
worldwide. This included a meeting in Dublin with 
WHO representatives where a range of items were 
reviewed and agreed in addition to a site visit to the 
meeting venue. The development of a dedicated 
conference website – icdra2018.ie – was also 
completed and commenced taking registrations in 
early 2018. 
– The UK withdrawal from the EU has potentially 
significant implications for the European health 
products sector and regulatory network as a whole 
and particularly for Ireland with its shared market 
place. Protecting the availability of medicines for 
Irish patients and the integrity of our market are key 
strategic aims of the HPRA’s Brexit-related activities 
while also optimising our role within the European 
regulatory network and maintaining our strong 
working relationships with UK colleagues. There 
were a number of Brexit-related initiatives either 
completed or progressed in 2017 including:
• A strategic review by the senior management 
of the implications of Brexit and the resulting 
HPRA response. A detailed, dedicated plan was 
agreed focusing on five key areas: communication, 
existing work, new work, stakeholder influence and 
resourcing. As part of the initial rollout of the plan, 
an internal working group was established with 
representatives from across each of the product 
areas regulated by the HPRA.
• In August, we held a successful stakeholder event 
which was attended by almost 300 delegates from 
the biopharma, medtech and life sciences sector. 
The meeting was one of the first opportunities 
for stakeholders from across the sector to meet 
and engage in respect of the challenges being 
presented by Brexit. The HPRA intends to host 
a further such meeting during the second half of 
2018 once greater clarity on the conditions and 
terms of the UK exit is available.
• The HPRA Brexit working group developed 
a detailed guidance document for industry 
stakeholders to complement similar information 
published at a European level. The guide was 
published in a newly established dedicated Brexit 
section on the HPRA website in December. 
• We participated in a number of speaking 
engagements to outline the potential impact on 
the Irish market and the planned HPRA Brexit 
strategy. 
• At a European level, we continue to be very active 
participants in initiatives and preparations linked 
to Brexit. This includes our high-level contribution 
to EMA activities and our membership of the HMA 
Brexit Task Force.
Additional key outreach and engagement figures
Year 2017
Public consultations launched:
 - Regulatory fees
 - Consultation on medical devices distributor  
  guidance
2
Public consultations we responded to:
 - Included CORU, Department of Health,  
  European Commission; Heads of Medicines  
  Agency, HSE, Medical Council and PSI
12
Events managed by HPRA events teams 16
Freedom of information requests 20
Requests received in accordance with the Data 
Protection Acts
2
Parliamentary questions 93
Queries from government departments or 
members of the Oireachtas
76
Protected disclosures received by external 
persons under section 7(2) of the protected 
Disclosures Act, of which investigation is: 
 - Concluded
 - Ongoing
7
1
Protected disclosures from HPRA staff members 0
Complaints 0
Customer service queries 3,096
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Organisation 
Development
The HPRA is committed to having the 
necessary corporate functions, systems and 
supports in place to deliver on our public 
health mission. We must ensure that our 
organisational capabilities continue to expand 
and evolve in line with regulatory and scientific 
developments and that we adapt to other 
changes in our operating environment. 
• BEMA
– The BEMA (Benchmarking of European Medicines 
Agencies) assessment of the HPRA’s management 
systems and systems for regulating human and 
veterinary medicines took place on 10 to 13 
October, by an assessment team from three other 
EU countries. The assessment against a range of 
indicators was thorough and challenging, with 
very positive results for the HPRA, including ‘best 
practices’ acknowledged in a number of areas. 
A small number of improvement actions will be 
addressed in 2018.
• Quality Management
– During 2017, the HPRA’s quality management 
system continued to be extended with the 
deployment of policies and procedures in 
preparation for the upcoming General Data 
Protection Regulation, new policies on risk 
management, energy and the internal audit 
strategy, and new procedures to better support 
innovation office queries and media queries. 
Guidance documents for stakeholders were 
published on the website including a guide to the 
notified body designation process, and a guide to 
scientific and regulatory advice for GXP activities.
– We continued our preparations for compliance 
with the General Data Protection Regulation 
(GDPR) which comes into force on 25 May 
2018. This included the establishment of a data 
processing register.
• Human Resources and Change
– Management and development of our staff is 
critical to the success of the HPRA’s regulatory 
functions. Using a framework of six core themes, 
our HR and Change Strategy 2016 – 2020 
identifies and delivers key supports required by the 
organisation to achieve its goals over the coming 
years. 
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During the year:
• We established a programme to further develop 
managerial capability in the HPRA and delivered 
three of the six modules of the management 
development programme to all managers in the 
organisation.
• A strategic approach to succession planning was 
developed and a key role review and forecasting 
analysis completed. Development plans were 
agreed and are underway. In addition, we began 
work on developing a scientific role skills matrix 
and approach agreed for the key role review. 
• A new graduate recruitment programme was 
launched, with an 18-month programme for two 
rotations to be offered to candidates in relevant 
scientific disciplines. By year-end, interviews 
were completed and candidates identified to 
commence their placements in September 2018. 
• We continued to deliver existing programme 
of activities, such as health and wellness 
programmes, organisational awareness fora and 
lunchtime learning. The receipt of a gold Active@
work award from the Irish Heart Foundation was 
recognition of our efforts in this regard.  
• Our LinkedIn presence was established with online 
recruitment testing in progress. 
• Medical Devices Department
– In consideration of the changing regulatory 
environment for medical devices, we reviewed the 
internal structures for the delivery of expanded 
functions with the management committee and held 
a number of workshops for staff. The subsequent 
report presented to the Authority identified the need 
for changes to the structure to allow us to effectively 
plan and implement the new EU Regulations. These 
involve bringing together in one department all 
medical devices staff except for the auditors who 
remain with the inspectorate section. Plans were 
underway by the end of the year to begin this process 
and recruit a head for the new department.
• Finance
– The 2017 financial statements presented in this 
report were prepared and submitted for audit to 
the Comptroller and Auditor General. All financial 
transactions during the period under review are 
reflected and reported upon in these statements 
as is our commitment to the highest standards of 
corporate governance.
– The annual review of regulatory fees for 2018 was 
completed following public consultation and resulted 
in the introduction of a modest general fee increase. 
Fees had not been increased by the HPRA since 2010 
with reduced fees introduced both in 2011 and 2012.
– Invoicing was introduced to support the 
introduction of a fee based funding model for the 
HPRA’s regulatory functions in respect of medical 
devices. The finance team engaged with relevant 
stakeholders as necessary in respect of the fees 
issued and payments received while monitoring the 
collectability rate on an ongoing basis. 
• Energy Usage
– The HPRA, as a public sector body, is required to 
report annually on its energy usage and actions 
taken to reduce consumption in accordance with 
the European Union (Energy Efficiency) Regulations 
2014 (S.I. No. 426 of 2014). As an organisation, we 
use electricity for lighting, air conditioning or heating 
as required and the provision of hot water; natural 
gas is used for central heating. In 2017, the HPRA 
consumed 804.5 MWh* of energy consisting of: 
• 600.5 MWh of electricity
• 203.9 MWh of fossil fuels
• 0 MWh of renewable fuels.
* these figures may differ from those officially published 
by the SEAI – official figures were not available at time 
of printing. 
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• IT Developments
– EOLAS is the HPRA’s new workflow technology 
solution, which will provide the organisation with 
a single workflow and data management system 
to support its regulatory activities. It will also 
incorporate new EU standards for regulatory data 
management. In 2017, the system was deployed 
to our Veterinary Sciences department in addition 
to the receipts and validations, and quality 
management sections. End users were supported 
through the provision of both general and role 
specific training and this was supplemented with 
training documents and online videos. Following 
go-live, end users worked closely with the project 
team to identify and manage any issues or 
adjustments required. This user insight supported 
ongoing preparations for deployment in 2018 to 
human medicines procedures.
– There were 417,211 regulatory submissions made 
through the Common Electronic Submission Portal 
(CESP), which is managed by the HPRA on behalf 
of the wider EU regulatory community. By year-
end, there were 5,000 organisations availing of 
CESP with over 12,000 individual users. 
– The HPRA participated, as part of a European 
consortium, in the European Commission’s Horizon 
2020 research programme on the openMedicine 
project that provided recommendations on the 
identification of medicines in a cross border 
setting, this project concluded in 2017.
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Committees
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• The Authority of the HPRA met six times in 2017 and 
considered a number of strategic matters including 
corporate policy, planning and financial matters. 
The latter included monthly management accounts, 
annual budgets and the financial statements for 
2016. The Authority also reviewed update reports 
from the Statutory Advisory Committees and the 
Audit and Risk Committee. In addition, it reviewed 
the licences for all medicinal healthcare products as 
approved by the Management Committee.
 The number of meetings attended by each Authority 
member during 2017 was as follows:
Authority 
Member
Number of 
meetings held 
during the 
period the 
member was on 
the Authority
Number of 
meetings 
attended during 
the period the 
member was on 
the Authority
Ms. Ann Horan 
(Chairperson)
6 5
Mr. Pat Brangan 6 6
Mr. Wilf Higgins 6 6
Mr. David 
Holohan
6 6
Prof. Mary Horgan 6 2
Mr. Brian Jones 6 6
Prof. Elizabeth 
Keane
6  6*
Prof. Caitriona 
O’Driscoll
6 6
Dr. Diarmuid 
Quinlan
6  5*
*One via T/C
– The Audit and Risk Committee, a subcommittee 
to the Authority, met four times in 2017. Further 
details are provided in the HPRA’s Financial 
Statements. 
– The Advisory Committee for Human Medicines 
met on one occasion in 2017. The Clinical Trials 
Sub-Committee is a sub-committee to the Advisory 
Committee for Human Medicines and it met twelve 
times in the past year.
– The Advisory Committee for Veterinary Medicines 
met twice as did the Advisory Committee for 
Medical Devices.
– The National Committee for the Protection of 
Animals Used for Scientific Purposes, a statutory 
committee to provide guidance to the regulator 
and those working in this area, met twice in 2017.
• Decisions of the Authority: 
 The terms of reference of the Authority, which are 
published on the HPRA website, include an overview 
of how the Authority operates, an overview of all 
decisions taken by the Authority and those devolved 
to the Management Committee. 
 The following decisions are reserved functions of the 
Authority: 
– The Authority takes decisions relating to very 
significant and serious public and/or animal health 
matters except in circumstances where a meeting 
of the Authority cannot be convened, in which case 
the Management Committee takes the decision and 
informs the Chairperson at the earliest opportunity 
and the Authority as soon as is practical. 
– The Authority refuses applications, or suspends, 
revokes or terminates authorisations as set out in 
legislation except in circumstances where: 
(a) the urgency is such that a meeting of the 
Authority cannot be convened, or 
(b) the application or authorisation is subject to a 
binding European decision, or 
(c) the application or authorisation is for a clinical 
trial or clinical investigation; in which case the 
Management Committee takes the decision 
and informs the Authority. 
– Through its Audit and Risk Committee, the 
Authority approves the internal financial controls 
and the financial audit function and satisfies 
itself that the financial controls and systems of 
risk management are robust and defensible. The 
Authority appoints the internal financial auditor. 
– The Authority approves the investment policy, 
major investments, capital projects and the terms 
of major contracts. 
– Significant acquisitions and the disposal or 
retirement of assets above a threshold set by the 
Authority are subject to Authority approval. 
– The Authority approves treasury policy and risk 
management policies. 
– The Authority approves corporate plans as 
required. 
– The Authority approves the annual budget, 
monitors expenditure and supervises the 
preparation and submission of the annual statutory 
accounts. 
– The Authority makes an annual report on the 
activities of the HPRA, including a financial 
statement, to the Minister for Health. This report is 
then published. 
– The Authority selects and appoints the Chief 
Executive, with the consent of the Minister for 
Health. The terms of office and the remuneration 
of the Chief Executive are determined by the 
Minister for Health, after consultation with the 
Authority and with the consent of the Minister for 
Finance. The Authority, through its Performance 
Review Committee, conducts a process of annual 
performance appraisal of the Chief Executive. 
Succession planning for the role of Chief Executive 
is also undertaken by the Authority. 
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Authority Members and Other Information
Authority: Most recent  
 appointment date Expiry date
Ms. Ann Horan (Chairperson) 01/01/2016 31/12/2020
Mr. Pat Brangan 22/05/2017 31/12/2019
Mr. Wilfrid Higgins 22/05/2017 31/12/2019
Mr. David Holohan 27/01/2016 26/01/2021
Prof. Mary Horgan 01/01/2016 31/12/2020
Mr. Brian Jones  27/01/2016 26/01/2021
Dr. Elizabeth Keane 22/05/2014 21/05/2019
Prof. Caitriona O’Driscoll 01/01/2016 31/12/2020
Dr. Diarmuid Quinlan 22/05/2014 21/05/2019
All Authority members are appointed by the Minister for Health.
Governance Statement and 
Authority Member’s Report
Governance
The Health Products Regulatory Authority (the HPRA) 
was established under the terms of the Irish Medicines 
Board Act, 1995 (as amended), and is governed by 
an Authority which was appointed by the Minister 
for Health. The Authority of the HPRA (the Authority) 
consists of a chairperson and eight non-executive 
members. The Authority is accountable to the 
Minister for Health and is responsible for ensuring 
good governance, and performs this task by setting 
strategic objectives and targets and taking strategic 
decisions on all key business issues. The regular 
day-to-day management, control and direction of the 
HPRA are the responsibility of the Chief Executive and 
the Management Committee. The Chief Executive 
and the Management Committee must follow the 
broad strategic direction set by the Authority, and 
must ensure that all Authority members have a clear 
understanding of the key activities and decisions 
related to the HPRA, and of any significant risks likely 
to arise. The Chief Executive acts as a direct liaison 
between the Authority and management of the HPRA.
On 1 July 2014, the organisation changed its name 
from the Irish Medicines Board, as provided for 
in Section 36 of the Health (Pricing and Supply of 
Medical Goods) Act 2013 and SI (205/2014) Health 
(Pricing and Supply of Medical Goods) Act 2013 
(Commencement) order 2014. 
Authority Responsibilities
The work and responsibilities of the Authority are 
set out in the Irish Medicines Board Act, 1995 (as 
amended), as well as in the ‘Terms of Reference 
and Rules of Procedure’ of the HPRA, which also 
contains the matters specifically reserved for Authority 
decision. Standing items considered by the Authority 
include:
• declaration of interests,
• reports from committees,
• financial reports / management accounts,
• performance reports, and
• reserved matters.
The Authority is required by the Irish Medicines Board 
Act, 1995 to prepare financial statements for each 
financial year which give a true and fair view of the 
state of affairs of the HPRA and of its surplus or deficit 
for that period.
In preparing those statements the Authority is 
required to:
• select suitable accounting policies and apply them 
consistently,
• make judgements and estimates that are reasonable 
and prudent,
• prepare the financial statements on a going concern 
basis unless it is inappropriate to presume that the 
HPRA will continue in existence, and
• state whether applicable accounting standards have 
been followed, subject to any material departures 
disclosed and explained in the financial statements.
 
The Authority is responsible for keeping adequate 
accounting records which disclose, with reasonable  
accuracy at any time, the financial position of the 
HPRA and which enable it to ensure that the financial 
statements comply with the Irish Medicines Board 
Act, with accounting standards generally accepted in 
Ireland and with accounting directions issued by the 
Minister for Health.  The maintenance and integrity of 
the corporate and financial information on the HPRA’s 
website is the responsibility of the Authority.
The Authority is responsible for approving the 
annual plan and budget. It is also responsible for 
safeguarding the assets of the HPRA and hence 
for taking reasonable steps for the prevention and 
detection of fraud and other irregularities.
The Authority considers that the financial statements 
of the HPRA give a true and fair view of the financial 
performance and the financial position of the HPRA at 
31 December 2017.
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Audit and Risk Committee
The HPRA has an audit and risk committee comprising 
three Authority members, which met on 4 occasions 
during 2017. This committee is responsible for 
reviewing internal control matters, together with 
any other issues raised by the external auditors, 
the Authority or management. The external auditor 
is invited annually to meet with the audit and risk 
committee to brief them on the outcome of the 
external audit, and the audit and risk committee also 
meets annually with the internal auditor. During 2017 
the internal auditor carried out internal audits on the 
areas of procurement and purchasing, as well as a 
review of compliance with the 2016 Code of Practice 
for the Governance of State Bodies. The audit and risk 
committee has also been involved with the review of 
the quality systems as described below.
Quality Systems
During 2017, the finance section of the HPRA 
continued the process of implementing and reviewing 
standard operating procedures (SOPs) under the 
quality management system. This process involved 
a critical review and analysis of internal controls and 
processes throughout the section with particular 
emphasis on risk management. This system now 
underpins the internal control environment and feeds 
into the internal audit process and ultimately into the 
audit and risk committee.
Remuneration Policy - Authority Members 
and Executive Directors
Remuneration and travel expenses paid to Authority 
members are disclosed in note 17 to the Financial 
Statements. The Chairperson receives remuneration 
as directed by the Minister for Health in accordance 
with the Irish Medicines Board Act, 1995. Other 
Authority members receive remuneration under the 
terms of the Health (Miscellaneous Provisions) Act 
2017. All Authority members are entitled to receive 
travel expenses in accordance with circulars issued 
by the Department of Health. The Chief Executive is 
remunerated in accordance with guidelines issued 
from Government and other Executive Directors are 
paid in accordance with Department of Health pay 
scales. The remuneration of the Chief Executive and 
Executive Directors are disclosed in note 18 to the 
Financial Statements.
Internal Control
The Authority is responsible for the HPRA’s systems 
of internal control. Such systems can only provide 
reasonable and not absolute assurance against 
material misstatement or loss. The systems of internal 
controls in use in the HPRA are described more fully in 
the Chairperson’s report on pages 47 to 48.
Disclosures Required by Code of Practice 
for the Governance of State Bodies (2016)
The Authority is responsible for ensuring that the 
HPRA has complied with the requirements of the 
Code of Practice for the Governance of State Bodies, 
as published by the Department of Public Expenditure 
and Reform in August 2016. The following disclosures 
are required by the Code, and are contained in the 
notes to the financial statements:
• employee short term benefits breakdown,
• consultancy costs,
• legal costs and settlements,
• travel and subsistence expenditure, and
• hospitality expenditure.
Statement of Compliance
The Authority has adopted the Code of Practice for 
the Governance of State Bodies (2016) and has put 
procedures in place to ensure compliance with the 
Code. The HPRA was in full compliance with the Code 
of Practice for the Governance of State Bodies for 
2017.
On behalf of the Authority
 
 
 
Date: 26 June 2018
Ms. Ann Horan 
Chairperson 
Mr. David Holohan 
Authority Member
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Statement on Internal Control
Scope of Responsibility
I, as Chairperson, acknowledge the Authority’s 
responsibility for ensuring that an effective system 
of internal control is maintained and operated. This 
responsibility takes account of the requirements of the 
Code of Practice for the Governance of State Bodies 
(2016).
Purpose of the System of Internal Control
The system of internal control is designed to manage 
risk to a tolerable level rather than to eliminate it. The 
system can therefore only provide reasonable and 
not absolute assurance that assets are safeguarded, 
transactions authorised and properly recorded 
and that material errors or irregularities are either 
prevented or detected in a timely way.
The system of internal control, which accords with 
guidance issued by the Department of Public 
Expenditure and Reform, has been in place in the 
HPRA for the year ended 31 December 2017 and up 
to the date of approval of the financial statements.
Capacity to Handle Risk
The HPRA has an audit and risk committee comprising 
three Authority members, which met on 4 occasions 
during 2017.
The HPRA has outsourced the internal audit function 
to an independent professional firm, who conduct a 
programme of work as agreed with the audit and risk 
committee. During 2017 two internal audit reviews 
were conducted.
The HPRA have developed a risk management 
framework, which sets out its risk appetite, the risk 
management processes in place and details the 
roles and responsibilities of staff in relation to risk. 
This framework has been made available to all 
staff, who are expected to work within the HPRA’s 
risk management policies, to alert management on 
emerging risks and control weaknesses, and assume 
responsibility for risks and controls within their own 
area of work. 
Risk and Control Framework
The HPRA has implemented a risk management 
system which identifies and reports key risks and the 
management actions being taken to address, and to 
the extent possible, to mitigate those risks.
A risk register is in place which identifies the 
key risks facing the HPRA, and these have been 
identified, evaluated and graded according to their 
significance. The register is reviewed and updated 
by management, considered by the audit and risk 
committee and presented to the Authority. The 
outcome of these assessments is used to plan and 
allocate resources to ensure risks are managed to an 
acceptable level.
The risk register details the controls and actions 
needed to mitigate risks and responsibility for 
operation of controls assigned to specific staff. I 
confirm that a control environment containing the 
following elements is in place:
• procedures for all key business processes have been 
documented,
• financial responsibilities have been assigned 
at management level with corresponding 
accountability,
• there is an appropriate budgeting system with an 
annual budget, which is kept under review by senior 
management,
• there are systems aimed at ensuring the security 
of the information and communication technology 
systems, and
• there are systems in place to safeguard the assets.
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Ongoing Monitoring and Review
Formal procedures have been established for 
monitoring control processes, and any control 
deficiencies are communicated to those responsible 
for taking corrective action, and to management and 
the Authority, where relevant, in a timely manner. 
I confirm that the following ongoing monitoring 
systems are in place:
• key risks and related controls have been identified, 
and processes have been put in place to monitor 
the operation of those key controls and report any 
identified deficiencies,
• reporting arrangements have been established at all 
levels where responsibility for financial management 
has been assigned, and
• there are regular reviews by senior management 
of periodic and annual performance and financial 
reports, which indicate performance against 
budgets.
Procurement
I confirm that the HPRA has procedures in place to 
ensure compliance with current procurement rules and 
guidelines, and that during 2017 the HPRA complied 
with those procedures.
Review of Effectiveness
I confirm that the HPRA has procedures to monitor 
the effectiveness of its risk management and control 
procedures. The HPRA’s monitoring and review of 
the effectiveness of the system of internal financial 
control is informed by the work of the internal and 
external auditors, the audit and risk committee which 
oversees their work, and the senior management 
within the HPRA, responsible for the development 
and maintenance of the internal financial control 
framework.
I confirm that the Authority conducted an annual 
review of the effectiveness of the internal controls for 
2017. This review was carried out at its meeting on 22 
March 2018.
Internal Control Issues
No weaknesses in internal control were identified in 
relation to 2017 that require disclosure in the financial 
statements.
Ms. Ann Horan 
Chairperson to the Authority 
Date: 26 June 2018
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Comptroller and Auditor 
General 
Report for presentation to the 
Houses of the Oireachtas
Qualified opinion on financial statements
I have audited the financial statements of the Health 
Products Regulatory Authority (the Authority) for the 
year ending 31 December 2017 as required under 
the provisions of section 18 of the Irish Medicines 
Board Act, 1995. The financial statements have been 
prepared in accordance with Financial Reporting 
Standard (FRS) 102 – The Financial Reporting 
Standard applicable in the UK and the Republic of 
Ireland and comprise
• The statement of income and expenditure and 
retained revenue reserves
• The statement of financial position
• The statement of cash flows and
• The related notes, including a summary of 
significant accounting policies.
In my opinion, except for the non-compliance with 
the requirements of FRS 102 in relation to retirement 
benefit entitlements referred to below, the financial 
statements give a true and fair view of the assets, 
liabilities and financial position of the Authority at 31 
December 2017 and of its income and expenditure for 
2017 in accordance with FRS 102.
Basis for qualified opinion on financial 
statements
In compliance with the directions of the Minister 
for Health, the Authority accounts for the costs of 
retirement benefit entitlements only as they become 
payable. This does not comply with FRS 102 which 
requires that the financial statements recognise the 
full cost of retirement benefit entitlements earned in 
the period. The effect of the non-compliance on the 
Authority’s financial statements for 2017 has not been 
quantified.
I conducted my audit of the financial statements 
in accordance with the International Standards on 
Auditing (ISAs) as promulgated by the International 
Organisation of Supreme Audit Institutions. My 
responsibilities under those standards are described 
in the appendix to this report. I am independent 
of the Authority and have fulfilled my other ethical 
responsibilities in accordance with the standards.
I believe that the audit evidence I have obtained is 
sufficient and appropriate to provide a basis for my 
opinion.
Report on information other than the 
financial statements, and on other matters 
The Authority has presented certain other information 
together with the financial statements. This comprises 
the annual report, the governance statement and 
Authority members’ report and the statement on 
internal control. My responsibilities to report in 
relation to such information, and on certain other 
matters upon which I report by exception, are 
described in the appendix to this report.
I have nothing to report in that regard.
Patricia Sheehan 
For and on behalf of the Comptroller  
and Auditor General 
Date: 29 June 2018 
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Appendix to the report 
Responsibilities of Authority Members
The governance statement and Authority 
members’ report sets out the Authority members’ 
responsibilities. The Authority members are 
responsible for
• The preparation of financial statements in the form 
prescribed under section 18 of the Irish Medicines 
Board Act 1995
• Ensuring that the financial statements give a true 
and fair view in accordance with FRS 102
• Ensuring the regularity of transactions
• Assessing whether the use of the going concern 
basis of accounting is appropriate, and
• Such internal control as they determine is necessary 
to enable the preparation of financial statements 
that are free from material misstatement, whether 
due to fraud or error.
Responsibilities of the Comptroller and 
Auditor General
I am required under section 18 of the Irish Medicines 
Board Act 1995 to audit the financial statements of 
the Authority and to report thereon to the Houses of 
the Oireachtas.
My objective in carrying out the audit is to obtain 
reasonable assurance about whether the financial 
statements as a whole are free from material 
misstatement due to fraud or error. Reasonable 
assurance is a high level of assurance, but it is not a 
guarantee that an audit conducted in accordance with 
the ISAs will always detect a material misstatement 
when it exists. Misstatements can arise from fraud or 
error and are considered material if, individually or in 
the aggregate, they could reasonably be expected to 
influence the economic decisions of users taken on 
the basis of these financial statements.
As part of an audit in accordance with the ISAs, 
I exercise professional judgement and maintain 
professional scepticism throughout the audit. In doing 
so,
• I identify and assess the risks of material 
misstatement of the financial statements whether 
due to fraud or error; design and perform audit 
procedures responsive to those risks; and obtain 
audit evidence that is sufficient and appropriate 
to provide a basis for my opinion. The risk of not 
detecting a material misstatement resulting from 
fraud is higher than for one resulting from error, 
as fraud may involve collusion, forgery, intentional 
omissions, misrepresentations, or the override of 
internal control.
• I obtain an understanding of internal control relevant 
to the audit in order to design audit procedures 
that are appropriate in the circumstances, but not 
for the purpose of expressing an opinion on the 
effectiveness of the internal controls.
• I evaluate the appropriateness of accounting 
policies used and the reasonableness of accounting 
estimates and related disclosures.
• I conclude on the appropriateness of the use of the 
going concern basis of accounting and, based on 
the audit evidence obtained, on whether a material 
uncertainty exists related to events or conditions 
that may cast significant doubt on the Authority’s 
ability to continue as a going concern. If I conclude 
that a material uncertainty exists, I am required 
to draw attention in my report to the related 
disclosures in the financial statements or, if such 
disclosures are inadequate, to modify my opinion. 
My conclusions are based on the audit evidence 
obtained up to the date of my report. However, 
future events or conditions may cause the Authority 
to cease to continue as a going concern.
• I evaluate the overall presentation, structure and 
content of the financial statements, including the 
disclosures, and whether the financial statements 
represent the underlying transactions and events in 
a manner that achieves fair presentation.
I communicate with those charged with governance 
regarding, among other matters, the planned scope 
and timing of the audit and significant audit findings, 
including any significant deficiencies in internal control 
that I identify during my audit.
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Information other than the financial 
statements
My opinion on the financial statements does not 
cover the other information presented with those 
statements, and I do not express any form of 
assurance conclusion thereon.
In connection with my audit of the financial 
statements, I am required under the ISAs to read 
the other information presented and, in doing so, 
consider whether the other information is materially 
inconsistent with the financial statements or with 
knowledge obtained during the audit, or if it 
otherwise appears to be materially misstated. If, 
based on the work I have performed, I conclude 
that there is a material misstatement of this other 
information, I am required to report that fact.
Reporting on other matters
My audit in conducted by reference to the special 
considerations which attach to State bodies in relation 
to their management and operation. I report if there 
are material matters relating to the manner in which 
public business has been conducted.
I seek to obtain evidence about the regularity of 
financial transactions in the course of audit. I report if 
there is any material instance where the public money 
has not been applied for the purposes intended or 
where transactions did not conform to the authorities 
governing them.
I also report by exception if, in my opinion,
• I have not received all the information and 
explanations I required for my audit, or
• The accounting records were not sufficient to permit 
the financial statements to be readily and properly 
audited, or
• The financial statements are not in agreement with 
the accounting records.
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 Note  2017  2016
  € €
Fee Income  3   24,033,010    21,461,418 
Department of Health Funding 3   2,941,000    3,916,000 
Other Income  4   655,238    1,090,096 
   
   27,629,248    26,467,514  
Salaries and Wages  5   20,284,686    18,684,512 
Other Operating Costs  6   6,650,642    5,138,378 
Depreciation  2   1,983,059    2,099,770 
   
   28,918,387   25,922,660 
 
Surplus/(Deficit) for the year before write
back of Superannuation contributions   (1,289,139)   544,854 
 
Staff Superannuation Contributions    924,064    746,723 
 
 
Surplus/(Deficit) for the year   (365,075)  1,291,577 
 
Balance brought forward     28,689,754    27,398,177 
 
Balance carried forward  12   28,324,679    28,689,754 
 
 
 
The Statement of Income and Expenditure and Retained Revenue Reserves includes all gains and losses recognised in the 
year. The Statement of Cash Flows and the notes on pages 55 to 64 form part of the financial statements.  
   
 
 
 
 
 
 
 
Statement of Income and Expenditure and Retained Revenue Reserves
For the year ended 31 December 2017
Ms. Ann Horan
Chairman
Date: 26 June 2018
On behalf of the Authority
Mr. David Holohan
Authority Member
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 Note  2017  2016
  € €
Fixed Assets  
Property, Plant and Equipment  2   25,339,839    26,039,261 
 
Current Assets
Debtors and Prepayments 7   1,404,687   1,129,190 
Inventory of Stationery   5,133    5,029 
Cash at Bank and in Hand 9   730,979    1,989,592 
Short Term Deposits 10  15,455,498    14,308,652  
   17,596,297    17,432,463 
Current Liabilities - Amounts falling
due within one year
Creditors and Accruals  8   9,058,113    8,435,294 
Mortgage  13   793,332    793,332 
   
   9,851,445    9,228,626 
 
Net Current Assets    7,744,852    8,203,837 
 
Long Term Liabilities - Amounts falling 
due after more than one year
Mortgage  13   4,760,012    5,553,344 
 
 
NET ASSETS    28,324,679    28,689,754 
 
 
Reserves
Retained Revenue Reserves  12   28,324,679    28,689,754  
  
   28,324,679    28,689,754 
 
 
 
 
Statement of Financial Position
As at 31 December 2017
Mr. David Holohan
Authority Member
Ms. Ann Horan
Chairman
Date: 26 June 2018
The Statement of Cash Flows and the notes on pages 55 to 64 form part of the financial statements.
On behalf of the Authority
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 Note  2017  2016
  € €
Cash flows from Operating Activities
 
Surplus/(Deficit) for financial year   (365,075)  1,291,577
Depreciation of property, plant and equipment  1,983,059  2,099,770
(Profit)/Loss on Disposal of property, plant and equipment  0  (20)
(Increase)/Decrease in Debtors  (275,497) 62,476
(Increase)/Decrease in Stock  (104) (2,952)
Increase/(Decrease) in Creditors - amounts  
falling due within one year  622,819 (352,528)
Deposit Interest   (21,965)  (35,829)
Bank Interest  200,601 222,798
Cash from Operations  2,143,838  3,285,292
Bank Interest Paid   (200,601) (222,798)
Net Cash generated from Operating Activities  1,943,237 3,062,494
Cash flows from Investing Activities  
Deposit Interest Received  21,965 35,829
(Increase)/Decrease in Bank Deposits   3,289 2,058,857
Payments to acquire property, plant and equipment   (1,283,637)  (2,473,473)
Receipts fom sales of property, plant and equipment  0  20
 
Net cash from Investing Activities  (1,258,383) (378,767)
Cash flows from Financing Activities
Repayment of Borrowings  (793,332)  (793,332)
Net cash used in Financing Activities  (793,332)  (793,332)
 
Net increase/(decrease) in Cash and Cash Equivalents  (108,478) 1,890,395
Cash and Cash Equivalents at beginning of year  3,992,528  2,102,133
 
Cash and Cash Equivalents at end of year 9  3,884,050 3,992,528
 
 
Statement of Cash Flows
For the year ended 31 December 2017
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Notes to the Financial Statements
For the year ended 31 December 2017
1. Accounting Policies    
      
A. General information   
 
The Health Products Regulatory Authority (HPRA) 
is a public statutory body established under the 
Irish Medicines Board Act 1995 (as amended). The 
principal place of business is at Earlsfort Centre, 
Earlsfort Terrace, Dublin 2. The Health Products 
Regulatory Authority is the competent Authority for 
the regulation of medicines, medical devices and 
other health products in Ireland.    
     
B. Compliance with FRS 102    
   
The financial statements of the HPRA for the year 
ended 31 December 2017 have been prepared in 
accordance with FRS 102 (the financial reporting 
framework applicable in the UK and Ireland), as 
modified by the directions of the Minister for Health 
in relation to superannuation. In compliance with the 
directions of the Minister for Health, HPRA accounts 
for the costs of superannuation entitlements only as 
they become payable (see K). This basis of accounting 
does not comply with FRS102, which requires such 
costs to be recognised in the year in which the 
entitlement is earned. The HPRA is availing of the 
reduced disclosures allowed by FRS 102 in relation 
to legal provisions, in instances where full disclosure 
might prejudice seriously its position in relation to 
disputes with other parties on the subject matter 
of the provision. In all other respects, the financial 
statements comply with FRS 102.    
    
C. Basis of preparation    
  
The financial statements have been prepared 
under the historical cost convention. The following 
accounting policies have been applied consistently in 
dealing with items which are considered material in 
relation to the Health Products Regulatory Authority’s 
financial statements.     
       
    
D. Critical accounting estimates and judgements
      
The preparation of the financial statements requires 
management to make judgements, estimates and 
assumptions that affect the amounts reported for 
assets and liabilities as at the reporting date and 
the amounts reported for revenues and expenses 
during the year. However, the nature of estimation 
means that actual outcomes could differ from those 
estimates. The following may involve a higher degree 
of judgement and complexity: 
  
(a) Provisions     
Provisions for legal obligations which it knows to be 
outstanding at the period-end date. These provisions 
are generally made based on historical or other 
pertinent information, adjusted for recent trends 
where relevant. However, they are estimates of the 
financial costs of events that may not occur for some 
years. As a result of this and the level of uncertainty 
attaching to the final outcomes, the actual outturn 
may differ significantly from that estimated. 
(b) Bad and Doubtful Debts   
The HPRA makes an estimate of the recoverable 
value of trade and other receivables. The HPRA 
uses estimates based on historical experience in 
determining the level of bad debts, which the 
Authority believes will not be collected. These 
estimates include such factors as the current credit 
rating, the aging profile, historical experience of the 
particular trade receivable and objective evidence of 
impairment of the asset. Any significant reduction in 
the level of bad debt provision would have a positive 
impact on the annual surplus/deficit. The level of 
provisioning required is reviewed on an on-going 
basis and has been disclosed in the notes to the 
financial statements. 
HPRA Annual Report 2017
Financial Statements
55
Notes to the Financial Statements
For the year ended 31 December 2017
E. Revenue recognition    
   
Revenue is measured at the fair value of the 
consideration received.    
- In the case of applications for marketing 
authorisations (new applications, variations to 
existing authorisations, or transfers) and clinical trial 
applications, income is recognised on a straight line 
basis over the specified timeline for the processing 
of the application by the Authority.
- In the case of wholesale and manufacturing licences 
and maintenance of marketing authorisations, fees 
are payable annually and a full year’s income is 
accrued in each financial year.    
       
  
F. Expenditure recognition   
    
Expenditure is recognised in the financial statements 
on an accruals basis.     
       
    
G. Reporting currency and currency 
translation      
 
The financial statements are prepared in euros. 
Transactions in currencies other than euro are 
recorded at the rates ruling at the date of the 
transactions or at a contracted date.  Monetary assets 
and liabilities are translated into euro at the reporting 
date or at a contracted date. Exchange differences are 
dealt with in the statement of income and expenditure 
and retained revenue reserves.    
    
       
  
H. Property, plant and equipment  
     
Plant and equipment excluding Premises
Plant and equipment excluding premises are stated 
at cost less accumulated depreciation. Depreciation 
is calculated in order to write off the cost of property, 
plant and equipment to their estimated residual 
values over their estimated useful lives by equal 
annual instalments.
The estimated useful lives of property, plant and 
equipment by reference to which depreciation has 
been calculated are as follows:    
   
Fixtures and Fittings:   5 years  
Computer Equipment :   3 years  
Improvements to Premises :  10 years 
       
   
Premises     
The HPRA purchased its premises at Kevin O’Malley 
House, Earlsfort Centre, Earlsfort Terrace, Dublin 2 
on 22 December 2004. The value capitalised was 
equal to the purchase price plus those costs directly 
attributable to bringing the asset into use. 
No depreciation has been calculated on the value 
of premises, as the remaining useful economic life is 
estimated to be greater than 50 years.   
     
       
I. Taxation      
 
The HPRA is exempt from liability to Corporation Tax 
under Section 227 of the Taxes Consolidation Act, 
1997.       
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J. Debtors      
 
Known bad debts are written off and specific provision 
is made for any amount the collection of which is 
considered doubtful.      
   
       
K. Superannuation     
  
The superannuation scheme operated by the 
HPRA is in accordance with the Local Government 
(Superannuation Revision) (Consolidation) Scheme, 
1986. It is an unfunded statutory scheme and benefits 
are met from current income as they arise. 
The scheme is a defined benefit scheme for 
employees. No provision has been made in respect 
of benefits payable. Pension payments under the 
scheme are charged to the income and expenditure 
account when paid. Contributions from employees 
who are members of the scheme are credited to the 
income and expenditure account when received. The 
surplus/(deficit) for the year is shown both before and 
after superannuation deductions. 
HPRA also operate the Single Public Service Pension 
Scheme. All new entrants into the public sector with 
effect from 1 January 2013 are members of this 
scheme, where all employee pension deductions are 
paid to the Department of Public Expenditure and 
Reform.
By direction of the Minister for Health, no provision 
has been made in respect of benefits payable in 
future years in relation to the Local Government 
(Superannuation Revision) (Consolidation) Scheme 
1986 or the Single Public Service Pension Scheme.  
      
       
  
L. Provisions      
 
A provision is recognised when the HPRA has a 
present obligation as a result of a past event, it is 
probable that this will be settled at a cost to the HPRA 
and a reliable estimate can be made of the amount of 
the obligation. 
M. Library      
 
No value has been placed on the books, audio-visual 
resources and electronic databases in the library.
Expenditure on these items is written off in the year in 
which it is incurred.     
   
       
N. Leases      
 
All leases are treated as operating leases and the 
rentals thereunder are charged to the Income and 
Expenditure account on a straight line basis over the 
lease period.       
       
   
O. Loans      
 
Loans are recognised initially at the transaction price 
(present value of cash payable, including transaction 
costs). Loans are subsequently stated at amortised 
costs. Interest expense is recognised on the basis 
of the effective interest method and is included in 
finance costs. 
Loans are classified as current liabilities unless there is 
a right to defer settlement of the loan for at least 12 
months from the reporting date.    
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2. Property, plant Fixtures and Computer  Leasehold Improvements Premises Total 
 and equipment Fittings Equipment Improvements To Premises   
  € € € € € €
  Cost
  Balance as at   1,205,593    14,590,308   502,445    4,364,198    23,156,037   43,818,581
  1 January 2017  
  Additions for the year   24,556    1,248,671  -   10,410   -  1,283,637
  Disposals for the year (2,753) (55,174) -  -  -  (57,927)
  As at 31 December 2017   1,227,396   15,783,805   502,445    4,374,608    23,156,037   45,044,291
  Depreciation
  Balance as at   1,119,006   12,408,607    502,445    3,749,262   -  17,779,320 
 1 January 2017
  Charge for the year   55,606    1,779,487  -   147,966   -  1,983,059
  Disposals for the year  (2,753) (55,174) -  -  -  (57,927)
  As at 31 December 2017   1,171,859   14,132,920    502,445    3,897,228   -  19,704,452
  Net Book value at  
 31 December 2017   55,537    1,650,885   -   477,380   23,156,037   25,339,839
  Net Book value at 
  1 January 2017   86,587   2,181,701  -  614,936    23,156,037   26,039,261
3.  Income  2017  2016
  €  €
 Fee Income
 Clinical Trials   192,843    181,082 
 Human Medicine - National Fees   6,196,699    6,324,512 
 Human Medicine - European Fees   7,050,808    6,853,136 
 Veterinary Medicine - National Fees   1,553,918    1,650,596 
 Veterinary Medicine - European Fees   1,499,930    1,288,314 
 Compliance Department   4,765,340   4,593,694 
 Medical Devices   2,920,161    400,817  
  
   24,179,699    21,292,151 
 Movement in deferred revenue (146,689)   169,267 
   24,033,010    21,461,418 
 Dept Of Health Funding (Vote 38 Subhead E1)   2,941,000   3,916,000  
 Other Income (Note 4)   655,238   1,090,096 
  
 Total Income   27,629,248   26,467,514 
 
 Certain fees received by the Authority under the Irish Medicines Board Act 1995 (as amended), totalling €19,055,338  
 in 2017, shall be paid into or disposed of for the benefit of the Exchequer in such manner as the Minister for Public  
 Expenditure and Reform directs.  
 The HPRA is in discussions with its parent department, as it is some years since the Minister has issued a directive in   
 relation to the fees under Section 13 of the IMB Act.   
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4.  Other Income
  2017  2016
  €  €
  
 Conference Fee Income   58,900    134,355 
 Deposit Interest   21,965    35,829 
 (Loss)/Gain on Disposal of Fixed Assets   -     20 
 IT Income   519,250   876,283 
 Zambia Project Income  55,123   43,609 
   
   655,238  1,090,096
5.  Salaries and Wages    
 
 Salaries and Wages    17,507,507    16,353,458 
 Pensions Paid    1,061,363    739,910 
 Social Welfare Costs   1,715,816    1,591,144 
   
   20,284,686    18,684,512 
 
  
 The average number of staff employed during the year was 327 (2016 - 312).   
 Payroll numbers at 31 December 2017 can be analysed across the following departments : -   
 
 
 Chief Executive  3  2
 Compliance  69  67
 Finance, Corporate & International  23  21
 Human Products Authorisation & Registration  110  111
 Human Products Monitoring  49  48
 Human Resources & Change  9  7
 IT & Business Services  19  21
 Quality, Scientific Affairs & Communications 12  11
 Veterinary Sciences  28  29
 Staff  322  317
 Authority Members 7  -
 Pensioners  38  34
  367  351
 
 
 No termination or severance payments were made during the year. 
 Pension related deductions for Public Servants of  €799,083 were deducted from staff during the year and paid over to   
 the Department of Health. 
 Pension deductions for Public Servants who are members of the Single Public Service Pension Scheme  
 of €203,178 were deducted from staff during the year and paid over to the Department of Public Expenditure  
 and Reform.
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 Salary Band 2017  2016
  
 €0 to €60,000    202  214
 €60,001 to €70,000    63  50 
 €70,001 to €80,000    13  9 
 €80,001 to €90,000    15  26 
 €90,001 to €100,000    22  9 
 €100,001 to €110,000    3  5 
 €110,001 to €120,000    1  2 
 €120,001 to €130,000    2  1 
 €140,001 to €150,000    1  1 
   
    322  317  
 
 Average Salary    €52.4K  €51.7K 
 
 Higher salaries relate primarily to scientific and other professional staff e.g. clinicians, pharmacists, veterinarians, lawyers  
 etc and are in accordance with Department of Health salary scales.  
6.  Operating Costs
  2017  2016
  €  €
  
 Accommodation Costs   1,177,395    1,186,524 
 Travel, Representation and Training   909,186    859,595 
 Bank Charges and Interest   207,643    229,547 
 Legal & Professional Fees   643,407    257,284 
 Stationery, Publications, Postage and Communications  637,177    698,613 
 Other Operating Costs   3,075,834    1,906,815 
   
   6,650,642   5,138,378 
  
  
 Travel costs include an amount of €12,120 related to Staff Hospitality, and an amount of €550,664 related to Travel and 
Subsistence, of which €205,853 is national and €344,811 is foreign.
Other Operating Costs include an amount of €325,354 related to consultancy costs, of which €167,007 relates to public 
relations/marketing.
 
7.  Debtors (all due within one year) 
 
 Trade Debtors   991,758    917,685 
 Prepayments   256,440    181,669 
 Other Debtors   156,489    29,836 
   
   1,404,687    1,129,190
Trade debtors are shown net of the bad debt provision. 
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8. Creditors (amounts falling due within one year)  2017  2016
  €  € 
 
 
 Trade Creditors   226,101    191,082 
 Accruals   7,018,843    6,508,352 
 Deferred Revenue   1,249,634    1,102,945 
 Revenue Commissioners   563,535    632,915  
  
   9,058,113    8,435,294 
9. Cash and Cash Equivalents  As At   As At
  01/01/2017  Cashflow  31/12/2017 
  
  
 Cash at Bank and in Hand   1,989,592   (1,258,613)  730,979 
 Demand Deposits   2,002,936   1,150,135   3,153,071 
 
  3,992,528  (108,478)  3,884,050
 
10. Short Term Deposits    2017  2016
   €  € 
 
 
 Demand Deposits (convertible to cash on demand) 3,153,071  2,002,936
 Short Term Deposits (not immediately convertible to cash) 12,302,427  12,305,716 
  
  15,455,498  14,308,652
 
11. Administration Expenses    
 
 Surplus for the year was calculated having charged : -   
 Auditor’s Remuneration   18,000  16,000
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12.   Movement on Income and Expenditure Reserves  As At   As At
 01/01/2017  Movement  31/12/2017 
  €  € € 
  
Retained Reserves   19,833,791  (1,289,139)   18,544,652 
Staff Superannuation Contributions  8,855,963    924,064    9,780,027 
 
   28,689,754   (365,075)  28,324,679 
 
13. Long Term Liabilities   
    
  Mortgage
On 22 December 2004 the HPRA purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, 
Dublin 2. The purchase was financed by way of a mortgage, secured on the premises of €20,400,000 over 20 years from 
Bank of Ireland Corporate Lending.    
  
  The HPRA is committed to making the following capital repayments on its mortgage : 
     
  2017  2016
      €  € 
 
  - within one year     793,332    793,332 
  - between one and five years     3,173,328    3,173,328 
  - after five years     1,586,684    2,380,016 
   
      5,553,344    6,346,676 
14. Interest Rate Exposure   
 
 The HPRA have taken all necessary steps to minimise its interest rate exposure by fixing 2/3s of the borrowings for the 
mortgage duration. The balance of the borrowings are fully offset by cash reserves. As the mortgage is at a fixed rate, 
the Authority has no interest rate exposure.     
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15. Financial Commitments
 Accommodation Costs (Note 6) includes expenditure of €285,984 in relation to operating leases. 
 
 On 28 January 2005 the HPRA signed a leasehold interest in respect of the 5th floor, Alexandra
 House, Earlsfort Centre, Dublin 2. At 31 December 2017 this lease had 4 years and four months remaining. 
   
    
  2017  2016
   €  €
 The amounts due under this lease are as follows:
 - within one year  285,984   285,984
 - between one and five years   953,280    1,143,936 
 - after five years  -   95,328 
   
   1,239,264    1,525,248 
16. Capital Commitments   
     
 Contracted For (Contract Signed)     1,775,842   2,094,971 
 Not Contracted For  -  -
   
   1,775,842    2,094,971 
 
17. Authority Remuneration
  
 Authority Members’ Fees   52,038    11,970 
 Authority Members’ Travel Expenses   4,362    8,284 
   
   56,400    20,254 
 Up to the 15th February 2017, other than the Chairperson, no other Authority Member received a salary. On 16th 
February 2017, the Health (Miscellaneous Provisions) Act was enacted, which made provision for payment of fees to 
other Authority members, provided that they were in compliance with the ‘one person one salary’ principle.
 
18. Key Management Personnel Remuneration
    
 Chief Executive   146,123   143,413 
 Senior Management   862,273    813,284 
   
   1,008,396    956,697 
  
  
 The Chief Executive’s and senior management’s pension entitlements do not extend beyond the standard entitlements 
in the model public sector defined benefit superannuation scheme.   
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19. Related Party Transactions
  
 There have been no transactions with related parties which require disclosure under Financial Reporting Standard 102.
20. Prompt Payment of Accounts
  
 The Health Products Regulatory Authority (HPRA) confirms that it is complying with EU law in relation to prompt 
payments of account.
21. Exchange Rates
  
 The exchange rates used in preparing these financial statements were as follows : -
  
 2017      €1 = STG £0.86470
 2016      €1 = STG £0.85637
22. Provisions
 
 The HPRA has been notified of a number of legal proceedings or potential proceedings. The Authority 
has provided in full for its ‘best estimate’ of the expenditure it is likely to incur in relation to those  cases. The Authority 
is availing of the reduced disclosures allowed by FRS 102 in instances where full disclosure might prejudice seriously its 
position in a dispute with other parties on the subject matter of the provision. 
23. Going Concern
 
 The HPRA has a reasonable expectation, at the time of appoving the financial statements, that the HPRA has adequate 
resources to continue its operations. For this reason, the HPRA continues to adopt the going concern basis in preparing 
the financial statements.     
 
24. Approval of Financial Statements
  
 The financial statements were approved by the Authority of the HPRA on 16 May 2018.
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Management Committee
Dr. Lorraine Nolan  
Chief Executive 
Ms. Rita Purcell   
Deputy Chief Executive
Dr. Gabriel Beechinor  
Director of Veterinary Sciences
Dr. Jayne Crowe   
Director of Human Products 
Authorisation and Registration
Dr. Caitríona Fisher   
Director of Quality, Scientific Affairs 
and Communications
Dr. Joan Gilvarry   
Director of Human Products 
Monitoring
Mr. Kevin Horan
Director of Information Technology 
and Business Services 
Mr. John Lynch   
Director of Compliance
Ms. Lynsey Perdisatt   
Director Human Resources and 
Change
Authority (Board)
Ms. Ann Horan – Chairperson
Dr. Patrick Brangan
Mr. Wilfrid Higgins
Prof. Mary Horgan
Mr. David Holohan
Mr. Brian Jones
Prof. Elizabeth Keane
Prof. Caitriona O’Driscoll
Dr. Diarmuid Quinlan
Audit Committee
Mr. Patrick Brangan – Chair
Mr. David Holohan
Prof. Elizabeth Keane
Advisory Committee for 
Human Medicines
Prof. Mary Horgan – Chair
Dr. Kevin Connolly
Prof. Desmond Corrigan
Ms. Maria Egan
Prof. Tom Fahey
Prof. David Kerins
Ms. Fionnuala King
Prof. Patrick Murray
Dr. Fionnuala Ní Ainle
Dr. Brian O’Connell
Mr. Ronan Quirke
Dr. Patrick Sullivan
Advisory Committee for 
Veterinary Medicines
Mr. Patrick Brangan – Chair
Dr. Ruadhrí Breathnach 
Ms. Eugenie Canavan
Dr. Martin Danaher
Dr. Helena Kelly
Dr. Nola Leonard
Dr. Bryan Markey
Dr. Ciaran Mellet
Dr. Warren Schofield
Dr. Robert Shiel
Dr. Christina Tlustos
Advisory Committee for 
Medical Devices
Mr. Wilfrid Higgins – Chair
Prof. David Barton
Dr. Vivion Crowley
Mr. Ger Flynn
Dr. Fergal McCaffrey
Ms. Margaret O’Donnell
Prof. Martin O’Donnell
Prof. Richard Reilly
Prof. Mary Sharp
Mr. Sean-Paul Teeling
Prof. Sean Tierney
Clinical Trial Sub-
Committee of Advisory 
Committee for Human 
Medicines
Dr. Patrick Sullivan – Chair
Dr. Liam Bannan
Dr. Geraldine Boylan
Dr. Paul Browne
Dr. Peter Crean
Prof. Lee Helman (CT Expert)
Dr. Filip Janku (CT Expert)
Dr. Catherine Kelly
Dr. Patrick Morris
Dr. Thomas Peirce 
Dr. Bryan Whelan
Dr. Jennifer Westrup
Experts Sub-Committee of 
the Advisory Committee 
for Human Medicines
Prof Mary Horgan – Chair
Dr Linda Coate
Dr Kevin Connolly
Mr James Colville
Dr Noreen Dowd
Dr Stephen Eustace
Prof Stephen Flint
Dr Tim Fulcher
Dr Joseph Galvin
Dr Patrick Gavin
Dr Paul Gallagher
Dr Kevin Kelleher
Dr Catherine Kelly
Dr Mary Keogan
Prof David Kerins
Dr Mark Ledwidge
Dr Frank Murray
Dr Yvonne O’Meara
Dr Cormac Owens
Dr Jogin Thakore
Dr Gerry Wilson
Advisory Sub-Committee 
for Herbal Medicines
Prof. Des Corrigan – Chair
Dr. James Barlow
Dr. Kevin Connolly
Mrs. Ingrid Hook
Ms. Claudine Hughes
Ms. Anna-Maria Keaveney
Dr. Celine Leonard
Dr. Donal O’Mathuna
Dr. Camillus Power
Dr. Helen Sheridan
Dr. Emma Wallace
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Third Level / Professional Development Presentations and Training 
Institution Course Presentation Title
Athlone IT Veterinary Nursing Regulation of Veterinary Medicines 
DIT Medical Device Decontamination 
(CPD)
Medical Devices Legislation / 
Medical Devices  Vigilance 
EU Network Training Centre Training Champions Workshop Scientific and Regulatory Training for 
Veterinary Medicines
IT Sligo Medical Biotechnology and  
Pharmaceutical Science
GMP, Quality Defects, Biological 
Medicines and Pharmacovigilance 
(Case Study based Workshop)
Letterkenny IT Veterinary Nursing Regulation of Veterinary Medicines 
NUIG / IT Sligo Medical Technology Regulatory 
Affairs
Medical Devices Legislation
RCSI Nurse/Midwife Prescribing The Role of the HPRA and 
Pharmacovigilance
RCSI Pharmacy Quality Defect in Medicines
RCSI Pharmacy Regulation of Similar Biological 
Medicines
RCSI Pharmacy Regulation of Biotechnology 
Therapeutics
RCSI Pharmacy Regulation of Generic and 
Interchangeable Medicines
RCSI Pharmacy Regulatory Affairs and Regulatory 
Authorities
RCSI Pharmacy Regulation of Medicine
St. Johns, Cork Veterinary Nursing Regulation of Veterinary Medicines 
TCD Hospital Pharmacy Authorisation of Medicines
TCD Immunology Regulation of Medicines / Regulation 
of Biological Medicines
TCD Pharmaceutical Medicine Risk Management Plans: An 
Overview
TCD Pharmaceutical Medicine Pharmacovigilance, Where are we 
Now?
TCD Pharmaceutical Medicine Communication of Drug Safety Data
TCD Pharmaceutical Medicine The Role of CMDh
TCD Pharmaceutical Medicine Overview of the Pharmacovigilance 
Risk Assessment Committee
TCD Pharmaceutical Medicine Regulation of Biologicals
TCD Pharmaceutical Medicine GCP Inspections
TCD Pharmaceutical Medicine Legal provisions Governing the 
SmPC, Package Leaflet and Labelling
TCD Pharmaceutical Medicine Traditional Herbal Medicinal Products 
(THMPs)
TCD Pharmaceutical Medicine Quality Standards and 
Pharmacopoeias
TCD Pharmaceutical Medicine Falsified Medicines Directive
TCD Pharmaceutical Sciences Regulation of Biologicals
TCD Pharmacy Overview of Pharmacovigilance
TCD Pharmacy Authorisation of Medicines and the 
Role of the HPRA
TCD Pharmacy Quality Defect in Medicines
TCD Regulatory Affairs Workshop Medical Devices Legislation
TCD Science The Role of the Regulatory 
Pharmacist
UCC Laboratory Animal Science and 
Training (LAST)
Legislative and Regulatory Aspects 
of Scientific Animal Protection
UCC PEARLL – Regulatory Support of 
Innovation
Innovation Benefits and Risks
UCC PEARLL – Regulatory Support of 
Innovation
Process Analytical Technology and 
Continuous Manufacturing
UCC Pharmacy Investigating and Reporting Quality 
Defects in Medicines
UCC Pharmacy Regulation of Biological and 
Biosimilar Medicines
UCD Bioengineering Medical Devices Legislation
UCD Clinical and Translational Medicine Medical Devices Regulation and 
Innovation
UCD Nurse/Midwife Prescribing The Role of the HPRA and 
Pharmacovigilance
UCD Regulatory Affairs and Toxicology Medical Devices Legislation
UCD Regulatory Affairs and Toxicology Pharmaceutical Regulatory Affairs
UCD Veterinary Medicine Regulation of Veterinary Medicines
University of Copenhagen Regulatory Affairs 
-Biopharmaceuticals
Biosimilars: Quality, Non-clinical and 
Clinical Requirements
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Event / Organiser Presentation Title
AFI (European Clinical Trial Day) The Future of Clinical Research
Association of the European Self-Medication Industry Reclassification of Medicinal Products in the Irish 
Regulatory Setting
BEAI Annual Conference Medical Device Innovation and Regulation
Beyond Compliance Meeting Medical Device Registries
BioProduction Congress Practical Advice on GMP Inspections
CASSS A Holistic Regulatory Approach to Accelerated CMC 
Development
Cattle Association of Veterinary Ireland Medicines Regulation - European Legislation Update
Chinese FDA New European Regulations on Medical Devices – 
Perspective of the HPRA
Curam MedTech Minds Medical Device Regulation
DIA Benefit Risk Strategies Workshop Referrals – Experience gained and Emerging Trends
DIA Conference Medical Device Regulation
DIA EuroMeeting 2017 SCOPE - Communicating Safety Information to 
Health Care Professionals in Europe
EDQM How to Build a Good CEP Application - ICH Q3D
EMA Stakeholder Day Future Opportunities for Pharmacovigilance
EU Medical Device Clinical Research Conference Medical Device Regulation
European Alliance for Personalised Medicine Growth in Personalised Healthcare
GS1 Ireland Healthcare User Group (HUG) Regulatory Update on Medical Devices
HISI Annual Conference Introduction to UDI in the MDR/IVDR
HISI Annual Conference Regulation of Medical Device Standalone Software
HSE (Registered Nurse Prescribers) The HPRA’s Exempt Medicinal Products Programme
Irish Medtech Association Regulation of Medical Devices – Increasing Patient 
Safety and Promoting Timely Innovation
Irish Medtech Association Sterility Assurance: Regulatory Expectations and 
Common Deficiencies
Klifovet, Munich Veterinary Medicines: A Review and Look into the 
Future of a National Competent Authority
MedTec Europe MEDDEV 2.7/1 Revision
MedTec Ireland Introduction to the new MDR
MedTec Ireland Medical Technology Sector in Ireland
National HPV Vaccine Conference Pharmacovigilance and HPV Vaccine
NUIG / HPRA Innovation Workshop Regulatory Pathway for Medical Devices in Europe
NUIG / HPRA Innovation Workshop HPRA Approach to CI Assessment under MDD
Regulatory Presentations  
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NSAI Notified Body Designation process
Official Medicines Control Laboratory Network Risk Assessment in Market Surveillance Testing 
Programmes
Parenteral Drug Association, Ireland Exploring the Concept of Formality and Informality 
in Quality Risk Management
PCR Innovators Day Medical Device Regulation
PDA Quality Risk Management Workshop Improvement Initiatives in relation to Quality Risk 
Management
Pharmaceutical Inspection Co-operation Scheme Validation Activities and Regulatory Expectations
Pharmig Annual Conference Contamination Control Strategy
PMDA, Japan Risk-based GMP Inspection Planning
QP Forum GMP Updates
Taking Care of Business (Department of Business,  
Enterprise and Innovation)
The Role of the HPRA and Our Support of 
Innovation
TÜV SÜD TAVI Valves
World Self-Medication Industry Regulators Forum Innovation in Medicines Reclassification
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Drug Safety Newsletters
Edition Topics
March
79th Edition
- Fluconazole – reminder not to use in pregnancy
- SGLT2 inhibitors and risk of lower limb amputation (mainly toe)
- Reports of keratoacanthoma with ingenol mebutate
- Adverse reaction reporting – reminder
- Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
April 
80th Edition
- Valproate-containing medicines – new EU review initiated
July
81st Edition
- Valproate (Epilim) and Developmental Disorders: Update on ongoing EU review
- Domperidone-containing medicines: reminder of the risk of cardiac adverse reactions-
restricted indication, contraindications and reduced dose and duration of use
- New CPD e-learning module on reporting suspected adverse drug reactions
August 
82nd Edition
- Daclizumab (Zinbryta) and risk of severe liver injury: initiation in multiple sclerosis now 
restricted, promptly review patients already on treatment
- Gabapentin – respiratory depression without concomitant opioid use
- Amoxicillin; co-amoxiclav – very rare reports of DRESS (drug reaction with eosinophilia and 
systemic symptoms)
November
83rd Edition
- Quinine – reminder of safety profile and potential drug-drug interactions particularly where 
used for nocturnal leg cramps
- Flucloxacillin and concomitant paracetamol – risk of high anion
- gap metabolic acidosis in very rare cases
- Epoetins: new warnings on Severe Cutaneous Adverse Reactions (SCARs)
- Adverse reaction reporting during 2016
December
84th Edition
- Conclusion of European Review of Gadolinium Contrast Agents – Publication of European 
Commission Decision
Appendix 3
Publications and Articles 2017
December 
85th Edition
- Daclizumab (Zinbryta) and risk of severe liver injury – EU wide review concludes and 
confirms further restrictions to reduce riskof liver damage
- New contraindication for injectable methylprednisoloneproducts containing lactose (Solu-
Medrone 40 mg / vial) in patients with cows’ milk allergy
- Warning about the use of Xofigo (radium-223 dichloride) in combination with Zytiga 
(abiraterone acetate) and prednisone or prednisolone: ongoing clinical trial shows an 
increased risk of death and fractures
Human Medicines Articles – External Publications
Month Publication Topics
January MIMS - Otezla (apremilast) – Important advice regarding suicidal 
ideation and behaviour
February IMF - Miconazole and Warfarin – Reminder of the potential for 
Interaction 
MIMS - Levetiracetam 100mg/ml Oral Solution- Global reports of 
medication errors resulting in the administration of higher than 
intended doses of levetiracetam
March MIMS - Lenalidomide (Revlimid) – Advice regarding viral reactivation
MIMS Respiratory 
Supplement
- Improved access to educational materials on the HPRA website
MIMS Cardiovascular 
Supplement
- Miconazole and warfarin - Reminder of the potential for 
interaction
April MIMS - SGLT2 inhibitors and risk of lower limb amputation (mainly toe)
May MIMS - Valproate-containing medicines – new EU review initiated (main 
edition)
MIMS Oncology 
Supplement
- Reports of keratoacanthoma with ingenol mebutate
June MIMS - Fluconazole – reminder not to use in pregnancy
MIMS Respiratory 
Supplement
- Advice on potential interaction between cobicistat-containing 
products and corticosteroids primarily metabolised by CYP3A: 
risk of adrenal suppression
July/August MIMS - Domperidone-containing medicines: Reminder  of the risk of 
cardiac adverse reactions restricted indication, contraindications 
and reduced dose and duration of use
MIMS Diabetes 
Supplement
- SGLT2 inhibitors and risk of lower limb amputation (mainly toe)
August IMF - Domperidone-containing medicines: Reminder of the risk of 
cardiac adverse reactions-restricted indication, contraindications 
and reduced dose and duration of use
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September MIMS - Amoxicillin; co-amoxiclav – very rare reports of DRESS (drug 
reaction with eosinophilia and systemic symptoms)
MIMS Pain 
Supplement
- Gabapentin – respiratory depression without concomitant 
opioid use
October MIMS - Daclizumab (Zinbryta) and Risk of Severe Liver Injury: Initiation in 
Multiple
- Sclerosis Now Restricted, Promptly Review Patients Already on 
Treatment
MIMS Women’s Health 
Supplement
- Reminder that Fluconazole Should Not be Used in Pregnancy
November MIMS - Epoetins: New Warnings on Severe Cutaneous Adverse 
Reactions (SCARs)
MIMS Diabetes 
Supplement
- High-Strength Insulin Preparations
December MIMS - New CPD e-learning module on reporting suspected adverse 
drug reactions
MIMS Compendium - Domperidone-containing medicines: Reminder of the risk of 
cardiac adverse reactions restricted indication, contraindications 
and reduced dose and duration of use
Human Medicines – Peer Reviewed and Conference Papers  
(HPRA Contributors)
Title Authors Publication / Event
Assessing awareness and attitudes of 
healthcare professionals on the use of 
biosimilar medicines: A survey of physicians 
and pharmacists in Ireland
O'Callaghan, J., Bermingham, 
M., Leonard, M., Hallinan, F., 
Morris, J.M., Moore, U. and 
Griffin, B.T.
Journal of Regulatory 
Toxicology and Pharmacology, 
88, 252-261
Knowledge of adverse drug reaction 
reporting and the pharmacovigilance of 
biological medicines: A survey of healthcare 
professionals in Ireland
O'Callaghan, J., Griffin 
B.T., Morris, J.M., and 
Bermingham, M.
BioDrugs Journal (accepted for 
publication) 
Assessing awareness and attitudes of 
healthcare professionals on the use of 
biosimilar medicines: A survey of physicians 
and pharmacists in Ireland
O'Callaghan, J., Bermingham, 
M., Leonard, M., Hallinan, F., 
Morris, J. M., Moore, U. and 
Griffin, B. T.
Presentation, Irish Nephrology 
Society Annual Scientific 
Meeting, Dublin, March 2017
Assessing awareness and attitudes of 
healthcare professionals on the use of 
biosimilar medicines: A survey of physicians 
and pharmacists in Ireland’
O'Callaghan, J., Bermingham, 
M., Leonard, M., Hallinan, F., 
Morris, J. M., Moore, U. and 
Griffin, B. T.
Poster, All Ireland Schools of 
Pharmacy Conference, Cork, 
April 2017
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Veterinary Medicines Articles – External Publications 
Publication Topic
Veterinary Ireland Journal The regulation of the scientific and educational use 
of large animals
Veterinary Ireland Journal Availability of veterinary medicinal products in 
Ireland
Veterinary Ireland Journal Antimicrobial resistance – update on European 
developments to control it
It’s Your Field Care in use and disposal of sheep dips
It’s Your Field Exceptional authorisation of veterinary medicines
It’s Your Field Pharmacovigilance inspections
New Industry Guidance Documents  
Document Title Month
Submission of Mock-Ups for Variations to Veterinary Products January
Placing Medical Device Standalone Software on the Market June
Scientific and Regulatory Advice for GXP activities October
Electronic Submissions – Medical Devices November
Notified Bodies – Designation Process November
Clinical Trials Regulation (EU) No. 536/2014 Pilot Project - Ireland December
Brexit Guidance - Human and Veterinary Medicines December
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European and National Committee / 
Working Group Participation
Committee/Working Group Organisation Meetings in 
2017
ARISg Regulatory Working Group ARIS Global 1
Counterfeiting of Medical Products (CMED) Council of Europe 2
Market Surveillance Forum Department of 
Business, Enterprise 
and Innovation
2
Medicinal Cannabis Expert Reference Group Department of Health 8
National Clinical Effectiveness Committee (NCEC) Department of Health 4
National Interdepartmental AMR Consultative Committee Departments of Health 
/ Agriculture, Food 
and the Marine
3
EDQM Committee Meetings EDQM 5
European Network of Official Cosmetics Control Laboratories 
(OCCL)  
EDQM 1
National Pharmacopoeia Authorities – Annual Meeting EDQM 1
OMCL (Official Medicines Control Laboratories) Network EDQM 1
OMCL Network Active Pharmaceutical Ingredient (API) Working 
Group
EDQM 1
OMCL Network Centrally Authorised Products (CAP) Working 
Group
EDQM 1
OMCL Network Communications Working Group EDQM 2
OMCL Network Counterfeit Products Working Group EDQM 2
OMCL Network Mutual Recognition and Decentralised procedures 
(MRP/DCP) Working Group
EDQM 1
OMCL Network Uncertainty of Measurement Working Group EDQM 2
Biological Working Party EMA 11
Biosimilar Medicines Working Party (BMWP) – including telecons EMA 8
Committee for Advanced Therapies (CAT) EMA 11
Committee for Herbal Medicinal Products (HMPC) EMA 6
Committee for Medicinal Products for Human Use (CHMP) EMA 11
Committee for Medicinal Products for Veterinary Use (CVMP) EMA 11
Committee for Orphan Medicinal Products (COMP) EMA 11
Good Clinical Practice (GCP) Inspectors’ Working Group EMA 4
Good Manufacturing and Distribution Practice (GMDP) Inspectors’ 
Working Group
EMA 4
Heparin Working Group EMA 3
Immunological Working Party - Veterinary EMA 3
Incident Review Network EMA 5
Joint Strategic Review and Learning Meetings – PRAC EMA 2
MAH Good Manufacturing Practice (GMP) responsibilities Working 
Group
EMA 4
Paediatric Committee (PDCO) EMA 12
Pharmacovigilance (PV) Inspectors’ Working Group (human) EMA 4
Pharmacovigilance (PV) Inspectors’ Working Group (veterinary) EMA 4
Pharmacovigilance Business Team EMA 15
Pharmacovigilance Risk Assessment Committee (PRAC) EMA 11
Pharmacovigilance Working Party - Veterinary EMA 6
Plasma Master File Meetings - telecon EMA 5
Process Analytical Technology – including telecon EMA 4
Quality Defects - Best Practices Working Group EMA 1
Quality Defects - Risk Working Group EMA 2
Quality Defects and Rapid Alert Working Group EMA 3
Quality Review of Documents working Groups EMA 3
Quality Working Party EMA 4
Safety Working Party - Human EMA 12
Safety Working Party – Veterinary EMA 4
Scientific Advice Working Party - Human EMA 11
Scientific Advice Working Party – Veterinary EMA 11
Signal Management Review Technical Working Group (Methods) – 
PRAC 
EMA 6
Signal Management Review Technical Working Group (SMART) 
Processes – PRAC 
EMA 9
Competent Authorities on Blood and Blood Components European Commission 2
Competent Authorities on Organ Donation and Transplantation European Commission 1
Competent Authorities on Tissues and Cells European Commission 2
Expert Group on Clinical Trials European Commission 6
Expert Group on Precursor Chemicals European Commission 2
Expert Working Group on Safety Features European Commission 6
Joint Action Market Surveillance of Medical Devices (MDs) European Commission 2
Medical Device – Vigilance MIR Form Development European Commission 2
Medical Device Compliance and Enforcement working group 
(COEN) – co-chair
European Commission 1
Medical Device Coordination Group European Commission 1
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Medical Device Expert Group Vigilance Working group European Commission 2
Medical Device Periodic Safety Update Reports Working Group European Commission 4
Medical Device Periodic Summary Report Working Group European Commission 4
Medical Device Vigilance Guideline Revision 9  European Commission 4
Open Conceptual Framework for Signal Detection and 
Management
European Commission 1
Platform of European Market Surveillance Activities in Cosmetics 
(PEMSAC) – Market Surveillance
European Commission 1
Standing Committee on Cosmetic Products European Commission 3
Working Group on Cosmetic Products European Commission 3
Vigilance and Inspection for the Safety of Transfusion, Assisted 
Reproduction and Transplantation (VISTART)  
European Commission 
/ Health and Food 
Executive Agency
7
Vigilance and Inspection for the Safety of Transfusion, Assisted 
Reproduction and Transplantation (VISTART)
European Commission 
/ National Competent 
Authorities
2
Operation MisMed Europol 2
Clinical Trials Facilitation Group (CTFG) HMA 6
Co-ordination Group for Mutual Recognition and Decentralised 
procedures – Human (CMDh)
HMA 11
Co-ordination Group for Mutual Recognition and Decentralised 
procedures – Veterinary (CMDv)
HMA 11
Homeopathic Medicinal Products Working Group HMA 2
Pharmacovigilance Worksharing Procedures Working Party HMA 6
Risk-based Surveillance Testing – Drafting Group HMA 4
Working Group of Communications Professionals HMA 2
Working Group of Enforcement Officers (WGEO) HMA 4
Working Group of Quality Managers HMA 2
National Cosmetics Surveillance Forum HPRA / HSE 2
IMDRF NCAR Exchange Review Working Group IMDRF 4
IPPOSI Round Table on Data Protection IPPOSI / Department 
of Health
1
Quarterly Haemovigilance Meetings NHO / HPRA 4
National Standards Authority of Ireland (NSAI) – Cosmetic 
Standards 
NSAI 2
Organ Vigilance Working Group ODTI / HPRA 2
Pharmaceutical Inspection Co-Operation Scheme (PIC/S) 
Committee of Officials
PIC/S 2
PIC/S Executive Bureau PIC/S 2
PIC/S Expert Circle on Quality Risk Management (QRM) PIC/S 6
Board of the UMC/WHO Collaborating Centre WHO 1
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